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I f  then Socrates we find  ourselves................. unable to make our discourse in
every way wholly consistent and exact you must not be surprised. Nay, we must 
be well content i f  we can provide an account not less likely than another; we 
must remember that I  who speak and you who are my audience are but men and 
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ABSTRACT
The major aim of the experiments described in this thesis was to 
investigate the putative mechanisms that are involved in the control of B- 
endorphin (B-END) secretion into the peripheral blood of the Soay ram. In 
addition, the effect of 8 -END and adrenocorticotrophin (ACTE1) on cortisol 
secretion was investigated.
A series of experiments was carried out to assess the influence of 
season, photoperiod, melatonin implantation, pinealectomy, castration and 
testosterone replacement on B-END secretion. There were significant changes 
in the plasma concentrations of B-END related to season and photoperiod in 
rams kept outside and inside, respectively. In outdoor rams B-END levels were 
highest in autumn and lowest in winter; in indoor rams the levels were highest 
during short days and lowest during long days. Melatonin implantation in 
outdoor rams from May to August caused a significant increase in B-END 
secretion, indicating a melatonin-induced short-day effect inspite of the 
prevailing long days. Pinealectomy disrupted the seasonal cycle in B-END 
secretion. Castration and testostrone replacement in indoor rams did not 
influence B-END secretion. These results indicate that B-END secretion is 
strongly influenced by season and photoperiod (via melatonin from the pineal 
gland) and that testosterone plays no role in B-END secretion.
In another series of experiments, the roles of arginine vasopressin 
(AVP), corticotrophin releasing factor (CRF), the synthetic glucocorticoid, 
dexamethasone (DEX) and the synthetic glucocorticoid antagonist, RU 486, in 
the control of the seasonal cycle in B-END secretion were investigated in 
spring, summer, autumn and winter. AVP and CRF given alone or in
combination significantly stimulated 8 -END secretion at all seasons and acted 
synergistically when given together. The responses were greater in summer 
and autumn than in winter and spring. DEX suppressed 8 -END secretion at all 
seasons and the responses were also greater in summer and autumn. DEX also 
blocked the AVP-induced increase in 8 -END secretion, indicating an action of 
DEX at the pituitary gland. RU 486 given in summer and winter significantly 
stimulated 8 -END secretion only in winter, indicating a seasonal variation in 
the negative feedback action of endogenous glucocorticoids. In addition, 
ACTH, but not 8 -END, significantly stimulated cortisol secretion at all seasons, 
with the greatest response in spring. These studies indicate that AVP, CRF and 
glucocorticoids are involved in the control of the seasonal cycle in 8 -END 
secretion; and that ACTH rather than 8 -END constitutes the " drive " to cortisol 
secretion.
The roles of dopamine (DA) and endogenous opioid peptides (EOP) 
in the control of 8 -END secretion were also investigated. The mixed DA 
antagonist, pimozide, significantly increased 8 -END secretion under long and 
short days; with a greater effect under long days.The D2  a g o n is t, 
bromocriptine, and the D2  antagonist, sulpiride, significantly decreased and 
increased, respectively, 8 -END secretion both under long and short days. The 
opioid antagonist, naloxone, had no effect on 8 -END secretion. These studies 
indicate that DA exerts an inhibitory control over 8 -END secretion while the 
EOP play no role in 8 -END secretion.
Based on the current results and a survey of the relevant literature, a 
model is proposed in which AVP, CRF, glucocorticoids on one hand, and DA 
on the other hand, are involved in the control of the secretory activity of 
corticotrophs and m elanotrophs in the pituitary gland. These central 
mechanisms are influenced by changes in photoperiod and other environmental 
factors to dictate the seasonal cycle in 6 -END secretion in the Soay ram, which
is low in winter and high in autumn. To fully assess the importance of AVP, 
CRF and DA in the seasonal control of 6 -END secretion, it will be necessary to 
directly measure the concentration of these hormones in the hypophysial portal 
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CHAPTER 1 
INTRODUCTION
The Soay breed of semi-domesticated sheep (Ovis aries ) originates 
from the island of St. Kilda (58°N) in the north Atlantic Ocean (Fig. 1.1). Like 
other mammals living in cold and temperate climates, the Soay sheep show 
many adaptations to living in a seasonal environment in which there are 
marked changes in daylength, temperature and food supply from summer to 
winter (Lincoln, 1989a). These adaptations include the occurrence of a 
seasonal cycle in reproduction with a restricted mating period in autumn, 
which is timed to produce offspring at a time of abundant food supply and 
warm conditions in spring (Lincoln and Davidson, 1977; Lincoln and Short, 
1980; Lincoln, 1989b). There are seasonal changes in pelage with a moult 
between summer and winter coats, allowing for a change in colour for 
camouflage and better insulation in winter (Ryder, 1971; Lincoln, 1989a). 
There are also conspicuous seasonal cycles in voluntary food intake, body 
growth and fattening to optimise the use of food which changes in both quantity 
and quality from summer to winter (Argo and Smith, 1983; Bronson, 1985). 
The physiological systems regulating these adaptative seasonal cycles are not 
well understood but clearly involve seasonal changes in the secretion of protein 
hormones from the pituitary gland. For example, there are seasonal changes in 
the circulating levels of FSH, LH, PRL and B-END (Lincoln and Short, 1980; 
Ebling and Lincoln, 1987). The seasonal cycle in reproduction is regulated by 
FSH and LH (Lincoln, 1988; 1989b), while that in moulting is controlled by 
TSH and PRL (Sutherland and Irvine, 1974; Ryder, 1979; Lincoln, Klandorf 
and Anderson, 1980; Lincoln and Ebling, 1985; Lincoln, 1989a). The 
regulation of the seasonal cycles in voluntary food intake, body growth and 
fattening involves complex mechanisms; however, changes in TSH, PRL, 
ACTH and B-END are thought to be involved in the regulation of these three 
seasonal variables (Ashmore and Morgan, 1967; Meier, 1977; Margules, 
1979; Baile, Kein, Della-Fera and McLaughlin, 1981; Ryg and Jacobsen, 1982;
2.
Fig. 1.1. A group of Soay rams which originate from the island of St. Kilda, 
160 km from  the mainland Scotland. They represent an early stage of 
domestication of sheep, having returned to the wild during the early settlement 
of the W estern Isles, and are well adapted to living in a seasonal environment, 
showing seasonal cycles in reproduction, moulting, food intake, body growth 
and fattening. (With permission from Lincoln and Short, 1980).
3-
Brinklow and Forbes, 1983; Baile et a l, 1987) (Fig. 1 .2 ).
The secretory activity of the pituitary gland is, in turn, governed by 
releasing and inhibiting factors from the hypothalamus. However, the way 
hypothalamic factors control seasonal changes in the secretion of pituitary 
hormones is poorly understood. The most comprehensive studies have been 
made on the regulation of the secretion of FSH and LH, which is dictated by 
changes in the release of GnRH from neurones in the hypothalamus. The 
hypothalamus is thought to play a key role in regulating all the seasonal 
adaptations since it relays the effects of environmental cues by way of 
modulating the release of releasing and inhibiting factors, which control the 
secretion of a diverse range of protein hormones from the pituitary gland 
which have specific target tissues around the body (Fig. 1.2).
Of particular interest is the recent observation that there are marked 
changes in the peripheral blood concentrations of 13-END in the Soay ram 
related to season and photoperiod (Ebling and Lincoln, 1987). In outdoor 
rams, there is a seasonal cycle in 13-END secretion; the levels increase about 20- 
fold from spring to autumn. This seasonal cycle in 13-END secretion is closely 
correlated with the seasonal changes in body weight and fattening; the increase 
in 13-END secretion occurs at a time when the rams are accumulating fat in the 
subcutaneous tissue, which suggests that 13-END may be involved in the 
deposition of fat reserves in anticipation of the harsh winter as proposed for 
other seasonal species by Margules (1979). In indoor rams, there is also a long­
term cycle in J3-END secretion; the levels are high under short days and low 
under long days, showing that photoperiod is probably the most important 
environm ental cue regulating the timing of the seasonal cycle in B-END 
secretion under natural conditions (Ebling and Lincoln, 1987).
The B-END in the peripheral circulation of the Soay ram is assumed to 
be secreted primarily from the pituitary gland since this tissue contains much
4.
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Fig. 1.2. Summary of the neuroendocrine relay by which environmental cues 
influence seasonal cycles in physiology and behaviour which represent 
adaptation to life in a seasonal environment
larger amounts of 6 -END compared with the hypothalamus (Ebling and 
Lincoln, 1987; Ebling et al., 1987). In the pituitary gland, there are two cell 
types which synthesize B-END from proopiomelanocortin (POMC), which is 
also the precursor for ACTH and a-M S H  (Antoni, 1986; Smith and Funder, 
1988) (Fig. 1.3). These are the corticotrophs in the anterior lobe which secrete 
B-END and ACTFt as their main products, and the melanotrophs in the 
intermediate lobe which co-secrete B-END and a-M SH . The neural control of 
the secretory activity of the corticotrophs and melanotrophs in the Soay ram is 
unknown. However, studies in non-seasonal species, including the rat and man, 
and those in other breeds of sheep show a parallel release of B-END and ACTH 
following treatment with corticotropin-releasing factor (CRF) and arginine 
vasopressin (AVP) which are thought to be the most important hypothalamic 
peptides regulating the activity of the corticotrophs (Antoni, 1986; Pradier, 
Dalle, Toumaire and Delost, 1988) (Fig. 1.3). Furthermore, there is a parallel 
release of B-END and a-M SH  following treatment with DA antagonists, which 
implicates the role of DA in the inhibitory control of the melanotrophs (Millan 
and Herz, 1985; Smith, Wallace, Clarke and Funder, 1989) (Fig. 1.3). In 
addition, glucocorticoids have been shown to inhibit the secretion of both B- 
END and ACTH in the rat and sheep (Donald, Redekopp, Cameron, Nicholls, 
Bolton, Livesey, Espiner, Rivier and Vale, 1983; Plotsky, Otto and Sapolsky, 
1986), and acute stressful stimuli stimulate the secretion of B-END, ACTH and 
a-M SH  (Nakao, Nakai, Jingami, Oki, Fukati and Imura, 1979; De Souza and 
Van Loon, 1985; Millan and Herz, 1985; Engler, Pham, Fullerton, Funder and 
Clarke, 1988). Thus, it is likely in the Soay ram, that B-END secretion into the 
peripheral blood represents the combined secretion from the corticotrophs and 
m elanotrophs, with the effects of photoperiod acting at the level of the 






















Fig. 1.3. General organisation of physiological mechanisms thought to control 
the secretion of 6 -endorphin and related peptides from the pituitary gland and 
the possible target tissues for these peptides in the Soay ram.
This study was undertaken with two main objectives. First, to provide 
more inform ation on the cycle in 6 -END secretion under different 
physiological states, paying particular attention to the influence of season, 
photoperiod and gonadal steroids. Second, to investigate the physiological 
control of the cycle in 6 -END secretion, paying particular attention to the role 
of CRF and AVP, adrenal glucocorticoids, dopamine (DA) and endogenous 
opioid peptides. The thesis starts with a review of the literature covering the 
isolation of 6 -END; the distribution of 6 -END and related peptides; the 
processing of 6 -END and related peptides from the POMC precursor in the 
pituitary gland; the regulation of the secretion of 6 -END and related peptides 
from the pituitary gland; and the physiological significance of 6 -END. The 
majority of the work on 6 -END has been done in the rat, but reports of studies 
in sheep and other animals are also given where available. Following the 
literature review, there is a chapter which describes the general materials and 
methods used in the study. Details of the experimental work are given in 
chapters 4, 5 and 6 , and each chapter includes a discussion pertinent to that 
particular series of experiments. The thesis concludes with a general discussion 
in which the major findings of the study are discussed in relation to the control 
of the seasonal cycle in 6 -END secretion and a model is proposed regarding the 
physiological mechanisms involved in this control.
CHAPTER 2 
REVIEW OF THE LITERATURE
9.
11 ISOLATION OF B-END
B-endorphin (B-END) is a peptide which belongs to one of the three 
families of endogenous opioid peptides called the endorphins; the other two 
being the enkephalins and dynorphins. B-END was first isolated as one of a 
series of fragments present in pig pituitary gland and was found to contain 31 
amino acids (Bradbury, Smyth, Snell, Birdsall and Hulme,1976). One of the 
fragments isolated with B-END was B-LPH, a 91-residue peptide that had been 
identified previously (Li, Bamafi, Chretien and Chung, 1965) and whose C- 
terminal sequence was shown to be identical to the sequence of B-END 
(residues 61-91) (Fig. 2.1); hence, B-END was initially named the " C- 
fragment" of B-LPH (Bradbury et al., 1976). A second group of peptides 
isolated from porcine pituitary included ACTH I -3 9  and its constituent 
fragments, a -M S H i -13  and C L IP ig .3 9 . Later, it was shown in both mouse 
pituitary tumour cells and in pituitary cell line At20/Di6v cells that B-END and 
the other pituitary peptides are derived from the same biosynthetic 31 
kilodalton precursor called proopiomelanocortin (POMC) (Mains, Eipper and 
Ling, 1977; Roberts and Herbert, 1977) (Fig. 2.1).
Investigation of the biological activity of the 31-residue peptide 
using dihydromorphine and naloxone revealed that it possesses opiate 
properties to an exceptional degree, both in vitro (Bradbury et al., 1976) and 
in vivo (Feldberg and Smyth, 1976, 1977; Loh, Tseng, Wei and Li, 1976); and 
rem arkably this peptide, though isolated from the pituitary, was found to 
exhibit its morphine-like effects on the brain. In view of the similarity of its 
properties to those of morphine, the general term endorphin (endogenous 
morphine), which had earlier been proposed by E. J. Simon for peptides with 
opiate activity (Goldstein, 1976), seemed appropriate when applied to B-LPH 
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Fig. 2 .1 . S tructural relationship  betw een peptides derived from  
proopiomelano-cortin.
After the demonstration that 6 -END was present in pig pituitary, it 
was isolated and sequenced in a variety of species, including the salmon 
(Kawauchi, Tubokawa and M uramoto, 1979; Kawauchi, 1983), frog 
(Martens, Civelli and Herbert, 1985), ostrich (Naude, Oelofsen and Maske, 
1980), m ouse (Uhler and Herbert, 1983), rat (Rubinstein, Stein and 
Udenfriend, 1978; Drouin and Goodman, 1980), sheep (Chretien, Benjannet, 
Dragon, Seidah and Lis, 1976; Ebling and Lincoln, 1987), camel (Li and 
Chung, 1976) and man (Chretien et al., 1976; Dragon, Seidah, Lis, Routhier 
and Chretien , 1977; Cochet, Chang and Cohen, 1982). It is notable that the 
amino sequence is strongly conserved with about 95% homology between 
positions 1 and 25 (Fig. 2.2). Such a strong conservation of structure in diverse 
species indicates that the full sequence of 6 -END may be important for its 
opioid and analgesic properties.
2 2  DISTRIBUTION OF 6 -END AND RELATED PEPTIDES
Immunohistochemistry and radioimmunoassay have been used to 
localise 6 -END and related peptides in a wide range of tissues, including the 
pituitary gland, the brain and peripheral organs (Guillemin, Ling and Vargo, 
1977a; Watson, Barchas and Li, 1977; Bloom, Battenberg, Rossier, Ling and 
Guillemin, 1978; Zakarian and Smyth, 1979; 1982a).
Immunohistochemical studies of rat pituitary gland, with antibodies 
to 6 -LPH or 6 -END, have shown that only some of the cells are reactive in the 
anterior lobe whereas all the cells are reactive in the intermediate lobe (Watson 
et al., 1977; Zakarian and Smyth, 1979; 1982a); a similar distribution is 
apparent in the sheep (Moon, Li and Jennings, 1973). Most recent evidence 
indicates that several POMC-derived peptides coexist in the same pituitary cell, 

































































possible to divide pituitary cells into corticotrophs and melanotrophs according 
to the way they process the POMC precursor. The corticotrophs are mainly 
located in the anterior lobe of the pituitary gland and synthesize primarily 
ACTH and 6 -END, whereas the melanotrophs are mainly located in the 
intermediate lobe and synthesize primarily cc-MSH and 6 -END (Antoni, 1986; 
Smith and Funder, 1988).
In the same studies that localised 6 -END and related peptides in the 
pituitary gland, it was demonstrated that these peptides are also localised in 
specific regions of rat brain. The main concentrations of 6 -END occur in the 
hypothalamus, and the cell bodies where biosynthesis takes place are located 
exclusively in this region, being concentrated in the arcuate nucleus. From the 
arcuate nucleus, nerve fibres extend to many regions of the brain, including the 
m edian em inence, am ygdala, preoptic area, ven trom edial nuclei, 
periaqueductal gray, reticular formation, stria terminalis, locus coeruleus, 
striatum and hippocampus (Watson et al., 1977; Gramsch, Kleber, Hollt, Pasi, 
Mehraein and Herz, 1980). In addition, Ibata, Kawakami, Okamura, Obata- 
Tsuto, Morimoto and Zimmerman (1985) have shown in both light and 
electron immuno-histochemical studies that 6 -END-positive staining neurons 
project to the portal capillaries of the external zone of the median eminence, 
suggesting the hypothalamus as a possible source of 6 -END in hypophysial 
portal blood. Furthermore, these studies have shown fibres extending to the 
ependymal layer of the third ventricle, suggesting that 6 -END and related 
peptides may be secreted into the cerebrospinal fluid.
Of particular relevancy to this thesis, is the distribution of 6 -END in 
the hypothalamus of the Soay ram characterised by extraction followed by 
radio-immunoassay. High 6 -END concentrations are detected in the mediobasal 
hypothalamus and median eminence; the immunoreactivity also extends to 
lateral and dorsal hypothalamus (Ebling, Lincoln, Martin and Taylor, 1987).
14.
Although there are significant amounts of 6 -END and related 
peptides in the hypothalamus, the total content is only a fraction (< 1%) of that 
found in the pituitary (Ebling and Lincoln, 1987; Ebling et al., 1987; Smith and 
Funder, 1988), indicating that the pituitary gland is the major source of 6 -END 
in the peripheral circulation.
6 -END and related peptides have also been localised in a variety of 
peripheral tissues, including the placenta (Genazzani, Hurlimann, Fioretti and 
Felber, 1974; Odagiri, Sherrell, Mount, Nicholson and Orth, 1979; Liotta, 
Loudes, McKelvy and Krieger, 1980), the thyroid gland (Clements, Funder, 
Tracy, Morgan, Campbell, Lewis and Hearn, 1982; Cheng, Smith and Funder,
1986), the adrenal gland (Vuolteenaho, Vakkuri and Leppaluoto, 1980; Evans, 
Erdelyi, W eber and Barchas, 1983), the antrum and pancreas (Fuerle, Weber 
and Helmstaedter, 1980; Tanaki, Yoshikatsu, Kazuwa, Oki, Masaki, Ohtsuki 
and Imura, 1982; Smyth, 1983), the spleen (Lolait, Lim, Toh and Funder, 
1984a), the male and female reproductive tracts (Sharp, Pekary, Meyer and 
Hersham, 1980; Tsong, Phillips, Halmi, Liotta, Margioris, Bardin and Krieger, 
1982; Lim, Lolait, Barlow, Zois, Toh and Funder, 1983; Lolait et al., 1984b; 
Shaha, Margioris, Liotta, Krieger and Bardin, 1984; Cheng et al., 1985; Li, 
Risbridger, Funder and Clements, 1989), the eye, pineal gland, kidney 
(Vuolteenaho et al., 1980) and the lungs (Clements et al., 1982).
2 3  PROCESSING OF 6 -END AND RELATED PEPTIDES FROM
THE POMC PRECURSOR IN THE PITUITARY GLAND
The pituitary gland is the major site of synthesis and secretion of 
circulating 6 -END (Ebling and Lincoln, 1987; Ebling et al., 1987; Smith and 
Funder, 1988); therefore, the way the POMC precursor is processed to 
produce 6 -END and related peptides will be considered only for this tissue.
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Fig. 2.3. Schematic diagram of pathways involved in the processing of the 
proopiom elanocortin precursor between the ribosome and the secretory 
vesicle.
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The processing events occur in two parts. The first part involves 
processing the POMC precursor before its complete translation; this occurs 
between the ribosome and secretory vesicle and is sometimes referred to as 
"maturation". This part applies to all cells that synthesize POMC. The second 
part is posttranslational and is tissue-specific; it involves a multiplicity of 
enzymes necessary for the production of the different peptides processed from 
POMC.
2.3.1 First part: processing between the ribosome and secretory vesicle
The first step in POMC processing between the ribosome and 
secretory vesicle is the removal of the N-terminal signal sequence (Fig. 2.3). 
The signal peptide, which is thought to play a key role in the cotranslational 
binding of ribosomes to the endoplasmic reticulum is cleaved from the 
precursor by a signalase enzyme; the cleavage occurs before complete 
translation as the precursor is entering the intracisternal space of the 
endoplasmic reticulum (Harwood, 1980). The second step involves a series of 
enzymatic events in which the asparagine residue in the Asn-X-Ser sequence 
after the y-MSH sequence is N-glycosylated; this also occurs to some extent in 
the CLIP sequence of rat POMC (Eipper and Mains, 1980). In the endoplasmic 
reticulum, a high mannose oligosaccharide core is attached to the asparagine 
residue of the polypeptide via a N-glycosidic linkage. After passage into the 
Golgi apparatus, glucose and mannose residues are "trimmed" from the core by 
glucosidases and mannosidases. In the third step, peripheral residues (N-acetyl- 
glucosamine, galactose and N-acetylneuraminic acid) are attached to the 
mannose residues of the core by glycosyl transferases. A less complex O-linked 
glycosylation (Lennarz, 1980) of Ser and Thr residues may also take place in 
the Golgi apparatus (Seidah and Chretien, 1981), where the attachment to the 
-OH group is probably through N-acetyl-galactosamine via O-glycosyl- 
transferases.
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2-3.2 Second part: processing in secretory vesicle and after secretion
This part of the processing involves a number of posttranslational 
events, including endopeptidase and exopeptidase cleavages, a-amidation and 
acetylation and, to a lesser extent phosphorylation and sulphuration. However, 
the extent to which these various events occur and the nature and amount of the 
peptides processed from POMC differ markedly between the anterior and 
intermediate lobes; these being determined by the distribution and controlled 
actions of the specific enzymes involved in each of the two lobes.
2.3.2.1 Processing in anterior lobe
In the rat anterior lobe, the principal products processed from 
POMC are B-LPH and ACTH; a significant portion of B-LPH is further 
processed to produce B-END (Mains et a i ,  1977; Eipper and Mains, 1980) 
(Figs. 2.1 and 2.3). The principal form of B-END is B-ENDi-3 1 , while smaller 
amounts of B-END 1-27 and B-ENDi-26 are produced. These are further 
metabolized to their respective N-acetylated derivatives, Nac-B-ENDi-3 1 , 
Nac-B-ENDi-27 and Nac-B-ENDi-26 (Zakarian and Smyth, 1982b) (Fig. 2.4). 
Other studies in the rat and man have shown that two smaller forms of 
endorphin, B-ENDi-17  (y-END) and B-END1- I 6 (a-END), are also present in 
the anterior lobe (Ling, Burgus and Guillemin, 1976; Burbach and Wiegant, 
1984) (Fig. 2.1). A similar processing pattern observed in the rat has been 
found to occur in a range of species, including the mouse, guinea pig, 
armadillo, cat, pig, sheep, cattle, monkey, baboon and man (Weber, Evans, 
Chang and Barchas, 1982; Zakarian and Smyth, 1982b; Smith and Funder,
1988). In most species, there is a low level of acetylation in the anterior lobe (< 
5%) (Smyth and Zakarian, 1980; Weber et al., 1982;), while the sheep is the 
exception in producing up to 25% of B-END in acetylated form (Smith and 
Funder, 1988).
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It should be emphasized that, although the POMC precursor is 
processed into all these various forms of 6 -END detectable in tissue extracts by 
immuno-precipitation, biosynthetic labelling experiments using intact cell 
suspensions have demonstrated that the major end product from POMC which 
is secreted is 6 -END 1.31  as the other forms of 6 -END are not detected in the 
medium after 6 h to 48h of pulse-chase incubations; even after 48h of 
incubation 75% of the 6 -END secreted is 6 -END 1 .3 1  (Mains and Eipper,
a-M SH  and CLIP are the other products processed from POMC in 
the anterior lobe (Fig. 2.1). In the rat, a-M SH is present in low amounts and is 
largely in the desacetyl form (Smith and Funder, 1988). In the sheep, a 
significant amount (25%) of ACTH is further processed to a-M SH; this has 
been characterized as desacetyl-a-MSH (30%), a-M SH (40%) and diacetyl-a- 
MSH (30%) (Smith and Funder, 1988).
23.2 .2  Processing in intermediate lobe
In the intermediate lobe, 6 -LPH and ACTH derived from the POMC 
precursor are further processed to produce 6 -END and y-LPH (Crine, 
Gianoulakis, Seidah, Gossard, Pezalla, Lis and Chretien, 1978; Mains and 
Eipper, 1979) and a-M SH and CLIP (Crine et al., 1979), respectively (Fig. 
2.1). Both 6 -END and a-M SH are extensively acetylated in the intermediate 
lobe. 6 -END is rapidly a-N-acetylated at the N-terminal tyrosine residue to 
produce acetyl-6 -ENDi_3 i; this is then slowly metabolized by proteolysis to 
produce acetyl 6-END 1-27 and acetyl-6-ENDi-26 (Eipper and Mains, 1981; 
Kizer, Bateman, Miller, Humm, Busby and Youngblood, 1986) (Fig. 2.4). a - 
MSH is acetylated at both the N and O positions of the amino-terminal serine 
residue (Rudman, Chawla and Hollins, 1979). These biochemical modifications 
have important effects on the biological activity of both 6 -END and a-M SH. 
For example, a-N-acetylation renders 6 -END inactive in terms of both opioid 






















































al., 1979). In contrast, acetylation of a-M SH markedly increases the potency of 
the peptide on melanocytes compared with desacetyl-a-M SH (Guttmann and 
Biossonnas, 1961). In the rat and sheep intermediate lobe, Nac-G-ENDi-27 is 
the principal form of acetylated endorphin as the there are two pathways for its 
production as illustrated in Fig. 2.4; Nac-B-ENDi-26 is also present in 
significant amounts (Smyth et al., 1979; Eipper and Mains, 1981; Smith et al.,
1987). However, whereas the shorter Nac-a-END and the Nac-y-END are 
relatively minor components in the rat, they constitute more than 60% of the 
total Nac-B-END in the sheep intermediate lobe (Smith and Funder, 1988). In 
both the rat and sheep, Nac-B-END 1.3 1  is a relatively minor component 
(Mains and Eipper, 1981; Smith and Funder, 1988).
In the rat, mouse and cattle intermediate lobe, a-M SH is diacetylated 
(Rudman et al., 1979; Al-Noaemi, Biggins, Edwardson, McDermott and Smith, 
1982; Goldm an, Beaulieu, Kebabian and Eskay, 1983). In the sheep 
intermediate lobe, however, desacetyl-a-MSH and diacetyl-a-M SH are present 
in approximately equal amounts (Smith and Funder, 1988).
2A  REGULATION OF THE SECRETION OF B-END AND
RELATED PEPTIDES FROM THE PITUITARY GLAND
There are im portant differences betw een the anterior and 
intermediate lobes of the pituitary gland in the way the hypothalamus regulates 
their secretory activity. The anterior lobe receives no direct neuronal inputs 
and is regulated by releasing and inhibiting factors which are released by the 
neurons in the hypothalamus into the portal blood vessels linking the median 
eminence with the pituitary gland. The intermediate lobe, in contrast, has a 
limited vascular supply and receives a neuronal input, in particular from the 
dopaminergic neurons in the arcuate nucleus, a population largely independent
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of its counterpart running to the median eminence (Bjorklund, Moore, Nobin 
and Steveni, 1973; Millan and Herz, 1985; Moore, 1987). (Fig. 1.3)..
2.4.1 Regulation of the anterior lobe
2.4.1.1 Regulation bv hypothalamic CRF and AVP
CRF is a 41-amino acid peptide isolated and characterized by Vale, 
Spiess, Rivier and Rivier (1981) from the hypothalamus of sheep, and is 
thought to play a key role in the regulation of the secretory activity of 
corticotrophs in the anterior lobe (Rivier, Brownstein, Spiess, Rivier and Vale, 
1982; Antoni, 1986; Smith and Funder, 1988). It is present in high amounts in 
the external median eminence and portal plasma, its content in the 
paraventricular nucleus is increased by adrenolectomy, and it promotes the 
secretion of B-END and related peptides from the anterior lobe (Rivier et al., 
1982; Burlet, Tonon, Tankosic, Coy and Vaudry, 1983; Swanson, Sawchenko, 
Rivier and Vale, 1983; Bruhn, Sutton, Rivier and Vale, 1984b; Antoni, 1986; 
Smith and Funder, 1988; Engler, Pham, Fullerton, Ooi, Funder and Clarke, 
1989b). Furthermore, CRF antibodies block the release of ACTH in vivo, e.g. 
in response to stress (Antoni, 1986).
AVP is the other hypothalamic peptide implicated in the regulation 
of anterior lobe corticotrophic activity. AVP produced from the para­
ventricular nucleus is similarly heavily represented in the extrenal median 
eminence (Levidiotis, Oldfield and W intour, 1987; W hitnall, Smyth and 
Gainer, 1987) and its concentration in the paraventricular nucleus is modified 
by glucocorticoid manipulations (Antoni, 1986; Smith and Funder, 1988). It is 
also found in portal plasma in large quantities and is a potent stimulant of the 
release of B-END and related peptides by a direct action on the anterior lobe 
(Buckingham,1987; Rivier et al., 1984; Lutz-Bucher, Kovacs, Makara, Stark 
and Koch, 1986; Pradier, Dalle, Tournaire and Delost, 1988; Engler et a'l.,
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1989b). Additional studies have found that AVP antisera block the ACTH 
releasing activity of median eminence extracts and introduction of antibodies 
against AVP in the brain partially blocks the release of ACTH induced by 
stimulation of the paraventricular nucleus (Carlson, Domhorst, Seif, Robinson 
and Gann, 1982; Linton, Gillies and Lowry, 1983). Indeed, colocalization of 
CRF with AVP in a subpopulation of AVP neurons projecting to the external 
median eminence has been reported (Burlet et al., 1983; Tramu, Croix and 
Pillez, 1983; Levidiotis et al., 1987; Whitnall et al., 1987).
Furtherm ore, both in vitro and in vivo, AVP potentiates the 
stimulatory action of CRF upon anterior lobe secretion (Rivier and Vale, 
1983a; Redekopp, Livesey, Toth and Donald, 1985b; Pradier et al., 1988). 
Thus, CRF and AVP coreleased in the median eminence may act synergistically 
on the anterior lobe to facilitate the secretion of 13-END and related peptides 
(Rivier and Vale, 1983a; Carlson and Gann, 1984). In addition, there is 
anatomical and physiological evidence that neural lobe stores of AVP may be 
involved in the modulation of anterior lobe corticotrophic activity (Millan and 
Herz, 1985; Antoni, 1986).
Mechanism o f  action : CRF stimulates the release of ACTH and 13-END from 
the corticotrophs and also induces an increase in the cellular levels of POMC 
mRNA and the synthesis of the POMC precursor (Bruhn et al, 1984b; 
Dallman, Makara, Roberts, Levin and Blum, 1985; Reisine, Rougon, Barbet 
and Affolter, 1985). The mechanism of action of CRF involves binding to 
specific, high affinity receptors in the anterior pituitary gland (Koch and Lutz- 
Bucher, 1983; Wynn, Aguilera, Morell and Catt, 1983; De Souza, Perrin, 
Rivier, Vale and Kuhar, 1984; Holmes, Antoni and Szentendrei, 1984; Perrin, 
Haas, Rivier and Vale, 1986). The binding of CRF to these receptors activates 
adenylate cyclase through a mechanism that requires magnesium ions and 
guanosine triphosphate (Aguilera, Harwood, Wilson, Morell, Brown and Catt,
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1983; Holm es et al., 1984; Perrin et al., 1986), thereby increasing the 
intracellular levels of cAMP and enhancing the activity of cAMP-dependent 
protein kinase(s) (Labrie, Veilleux, Lafevre, Coy, Sueras-Diaz and Schally, 
1982; Aguilera et al., 1983; Erlichman, Litvin and Fleischer, 1984; Miyazaki, 
Reisine and Kebabian, 1984). Derivatives of cAMP, as well as agents that 
increase the intracellular levels of this second messenger, mimic the effects of 
CRF in all respects (Axelrod and Reisine, 1985). CRF also increases the levels 
of cytosolic free calcium and it has been suggested that influx of calcium from 
the extracellular medium is associated with the stimulation of ACTH release by 
CRF, and that this is caused by cAMP (Luini, Lewis, Guild, Corda and 
Axelrod, 1985). There is also a possibility that CRF acts via the arachidonic 
pathway. A mechanism alternative to cAMP, which may serve to increase 
intracellular calcium levels by causing influx of calcium  ions from the 
extracellular medium, is the generation of arachidonic acid metabolites via the 
cyclooxygenase and/or lipoxygenase pathways of arachidonic acid metabolism 
(Naccache, Showell, Becker and Sha'afi, 1979).
There is evidence that the direct action of AVP on corticotrophs 
and the indirect action of AVP in potentiating the effect of CRF are mediated by 
two different types of receptor. That mediating the direct action of AVP on the 
anterior lobe corticotrophs has many properties in common with the V i 
pressor type AVP receptor (Manning and Sawyer, 1984), but can be clearly 
differentiated by its low affinity for potent V i receptor antagonists (Antoni, 
1984). In fact, V i antagonists are partial agonists in stimulating ACTH release 
and they also act synergistically with CRF (Antoni et al., 1984; Knepel, 
Homolka, Vlaskovska and Nuto, 1984; Rivier et al., 1984; Rivier and Vale, 
1985; Buckingham, 1987). The AVP receptor involved in the potentiation of 
CRF activity is not fully characterized but appears to be neither V i- nor V2 - 
receptor (Buckingham, 1987). Knepel et al. (1984) have suggested that the two
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distinct actions of AVP on the anterior pituitary gland, which appear to be 
effected by different parts of the molecule, could be explained either by a single 
binding site mediating both responses by different mechanisms or, more 
feasibly, by the existence of two receptors with similar binding characteristics. 
Extracellu lar calcium is required for the stim ulation of anterior lobe 
corticotrophic secretion by AVP (Zimmerman and Fleischer, 1970), but the 
direct action of AVP does not require cAMP (Axelrod and Reisine, 1985) 
instead, it seems to involve the activation of the calcium-calmodulin kinase C 
pathway. This is supported by a number of studies which explain the synergistic 
action between CRF and AVP in terms of an interaction between the cAMP- 
dependent and the calcium-calmodulin-kinase C-dependent pathways (for 
review see Rasmussen, Kojima, Kojima, Zawalich and Apfeldorf, 1984). 
Another site where the actions of CRF and AVP may converge is the 
arachidonic acid pathway. For example, the A VP-induced ACTH release has 
been shown to be inhibited by blockers of lipoxygenase and enhanced by 
indomethacin, a blocker of cyclooxygenase (Vlaskovska and Knepel, 1984; 
Vlaskovska et al., 1984).
2.4.1.2 Regulation bv adrenal glucocorticoids
Glucocorticoids, secreted from the adrenal gland under the stimulus 
of ACTH have a negative feedback action on anterior lobe corticotrophic 
activity (Giguere, Labrie, Cote, Cory, Suerias-Diaz and Schally, 1982; Antoni, 
1986; Plotsky et a l,  1986; Smith & Funder, 1988). Glucocorticoids not only act 
directly on the anterior lobe to suppress corticotrophic secretion, they also act 
centrally to suppress the release of CRF and AVP (Buckingham, 1979; 
Sakakura, Yoshioka, Kobayashi and Takebe, 1981; Carnes, Barksdale, Kalin, 
Brownfield and Lent, 1987). In vitro studies have clearly demonstrated the 
potent suppressive effects of glucocorticoids on both the CRF-induced release 
of 6 -END and ACTH in cultured anterior lobe cells and the release and
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generation of CRF (Guillemin, Vargo, Rossier, Minick, Ling, Rivier, Vale and 
Bloom, 1977b; Antoni, 1986). These studies have been corroborated by the 
observation that the synthetic glucocorticoid, dexamethasone, administered in 
vivo causes a rapid decrease in CRF content of rat median eminence ( Suda, 
Tomori, Tozawa, Mouri, Damura and Shizume, 1984 ).
Mechanism o f action : Glucocorticoids act at both the central and pituitary 
levels to regulate the secretion of 6 -END and related peptides from the anterior 
lobe. Studies on the hypothalamic distribution of glucocorticoid receptors, 
either by immuno-histochemistry using monoclonal antibodies against the 
glucocorticoid receptor (Fuxe, W ikstrom, Okret, Agnati, Hafstrand, Yu, 
Granholm, Zdi, Vale and Gustafsson, 1985) or radioligand assays in micro­
dissected areas (Reul and De Kloet, 1985), confirm that the paraventricular 
nucleus contains feedback type glucocorticoid receptors, which are apparently 
present in the parvicellular compartment (Reul and De Kloet, 1985). Systemic 
administration of glucocorticoids has been shown to prevent the adreno- 
lectomy-induced increase of CRF immunostaining (Sawchenko and Swanson, 
1984) and to reduce the hybridizable A VP mRNA in the parvicellular neurons 
of the rat hypothalamus (Davis, Arentzen, Reid, Manning, Wolson, Lawrence 
and Baldino, 1986). In a most elegant experiment, Kovacs, Kiss and Makara 
(1986) showed th a t, in the rat, unilateral implantation of dexamethasone in the 
vicinity of the paraventricular nucleus blocked the increase in immunostaining 
of CRF and AVP after adrenalectomy. Implants in the central amygdala had no 
effect on the CRF cells locally or in the paraventricular nucleus; furthermore, 
implants in the dorsal hippocampus also failed to prevent the paraventricular 
nucleus response to adrenalectomy (Kovacs et al., 1986). In addition, Kovacs 
and M ezey (1987) have dem onstrated that unilateral im plantation of 
dexamethasone around the paraventricular nucleus results also in a decrease of 
hybrid izab le  CRF mRNA at the dexam ethasone-im plan ted  side. 
Dexamethasone implants into the cerebral cortex, dorsal hippocampus, ventral
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subiculum, lateral septum or amygdala were without any effect on the CRF 
expression in the paraventricular nucleus. Interestingly, corticosterone did not 
result in any significant change in the CRF mRNA when implanted into the 
paraventricular region; however, when it was placed into the amygdala it 
slightly inhibited the CRF mRNA levels in the ipsilateral paraventricular 
nucleus in a few cases (Kovacs and Mezey, 1987). These observations strongly 
suggest that a glucocorticoid receptor system is present in the paraventricular 
nucleus and is involved in the regulation of the expression of CRF and AVP by 
hypophysiotrophic CRF neurons.
The precise mechanism of glucocorticoid feedback action at the 
pituitary level is not clear.There is evidence that the inhibitory feedback action 
of glucocorticoids on the pituitary gland involves the activation of genes 
through binding of the hormone-receptor complex to promoter element in cell 
nuclear chromatin (Lan, Karin, Nguyen, Weisz, Bimbaum, Eberhardt and 
Baxter, 1984). This is followed by the initiation of mRNA transcription from 
the activated gene(s) with subsequent synthesis of new proteins. One of the 
glucocorticoid-induced proteins is lipocortin, an inhibitor of phospholipase A2  
(Hirata, Schiffman, Venkatabramanian, Salomon and Axelrod, 1980). In 
principle, inhibition of this enzyme could reduce the B-END/ACTH-releasing 
action of CRF and AVP (Vlaskovska and Knepel, 1984). On the other hand, 
since feedback inhibition is associated with a reduction of the POMC mRNA in 
corticotrophs (Eberwine and Roberts, 1984) while cAMP increases POMC 
mRNA, it has been suggested that the inhibition of corticotrophic secretion by 
glucocorticoids involves a reduction in the ability of the cAMP-dependent and 
C protein kinases to phosphorylate their specific substrates (Antoni, 1986). It 
should be noted, however, that glucocorticoids do not completely inhibit the 
corticotrophic-stimulating action of CRF (Bilezikian and Vale, 1983; Giguere 
et al., 1982), which indicates that perhaps only one branch of the transducing 
pathw ay activated by CRF is affected by this feedback action of
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glucocorticoids. A fast feedback inhibitory action of glucocorticoids on 
corticotrophic secretion has also been described (Keller-W ood and Dallman, 
1984; Widmaier and Dallman, 1984), but the mechanism of action is yet to be 
identified.
2.4.2 Regulation of the intermediate lobe
2.4.2.1 Regulation bv hypothalamic DA
The intermediate lobe of the pituitary gland is under tonic inhibition 
by DA. This is based on the observation that disconnection of the pituitary stalk 
results in hypertrophy of the cells of the intermediate lobe and increased 
secretion of 6 -END and a -M S H  (Clarke, Clements, Cummins, Dench, Smith, 
Robinson and Funder, 1986). These peculiarities are accounted for by the 
interruption of a tonic inhibitory influence acting upon the intermediate lobe. 
Indeed, a component of the tuberohypohysial dopaminergic system arises in the 
rostral arcuate nucleus and sends fibres to the interm ediate lobe, where 
dopaminergic neurons make synapse-like contact with the pituitary cells 
(Moore, 1987). (Fig. 1.3). It is this component that inhibits intermediate lobe 
melanotrophic secretion of 6 -END and a-M SH . For example, DA and 
congeners have been shown, in vitro, to dose-dependently block spontaneous 
action potentials and the release of 6 -END and a-M SH  via an action at DA 
receptors of the D2  subtype (Vale et al., 1979; Vermes, Mulder, Smelik and 
Tilders, 1980; Cote et al., 1982a). In vivo studies have corroborated the picture 
of a dopaminergic brake upon melanotrophic secretion of 6 -END and a-M SH. 
Levels of these peptides in the systemic circulation are increased by DA 
antagonists (Farah, Malcolm and Mueller, 1982; Chen, Dionne and Roberts, 
1983; Kemppainen, 1986; Smith, Wallace, Clarke and Funder, 1989), and 
chronic exposure to these antagonists causes a rise in intermediate lobe content 
of 6-END and a-M S H  and the amount of mRNA coding for POMC (Hollt and
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Bergman, 1982; Chen et al., 1983; Chronwall, Millington, Griffin, Unnerstall 
and O'Donohue, 1987). Jenks, Verburg van Kemenade, Tonon and Vaudry
(1985) have also observed that in the frog (.Rana ridibunda ) intermediate lobe, 
DA inhibits the acetylation of a-M SH (and 6 -END).
Mechanism o f action : The action of DA on intermediate lobe melanotrophs has 
been shown to be mediated by D2  receptors (Kebabian and Caine, 1979; Cote et 
al., 1982a,b; Creese, Sibley, Hamblin and Leff, 1983; Farah and Mueller,
1989). The physiological consequence of stimulating these receptors is a 
reduction in both calcium entry and the synthesis of cAMP in the melanotrophs, 
which results in a decrease in secretion (Munemura, Cote, Tsuruta, Eskay and 
Kebabian, 1980a,b; Cote et al., 1981; Cote e ta l ,  1982b).
Dopaminergic drugs have also been shown to alter the production 
of POMC mRNA and the rate of a-N-acetylation in the intermediate lobe. For 
example, Hollt, Haarmann, Seizinger and Herz (1982) and Chen et al. (1983) 
found that treatment of male rats with the DA antagonist, haloperidol, results in 
a time-dependent increase in POMC mRNA levels. More recently, Millington, 
O'Donohue, Chappell, Roberts and Mueller (1986) have also demonstrated that 
chronic treatment of rats with haloperidol not only increased levels of mRNA 
coding for POMC but also caused an essentially parallel rise in a-N -acetyl- 
transferase activity in the intermediate lobe.
2,5 MODULATION OF THE SECRETION OF B-END AND
RELATED PEPTIDES BY OPIOIDS AND GONADAL
STEROIDS
2.5.1 Modulation bv opioids
The administration of opioid agonists to rats induces the secretion 
of ACTH as reflected by a rise in glucocorticoid levels, an action which 
develops tolerance (Buckingham, 1979; Buckingham & Cooper, 1984; Jezova,
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Jurcovicova, 1982; De Souza & Van Loon, 1982). This appears to be a central 
effect mediated via anterior lobe pools of ACTH since it is abolished by 
hypophysectomy, treatment with dexamethasone, or lesions of the median 
eminence. The effect is reproduced by administration of opioids into the brain, 
and is accompanied by a rise in serum 8 -END and ACTH (Buckingham, 1979; 
Jezova et al., 1982; De Souza & Van Loon, 1982; Antoni, 1986). These changes 
appear to involve the central action of opioids on the secretion of CRF and AVP 
since, in vitro, the anterior lobe secretion of 8 -END and ACTH is not affected 
by opioids, whereas these compounds stimulate hypothalamic release of CRF 
(Buckingham, 1982; Buckingham and Cooper, 1984). Also, the rise in ACTH 
after opioids administration in vivo has been shown to be associated with 
changes in hypothalamic levels of CRF (Buckingham, 1982; Antoni, 1986). 
However, it is evident that the interaction of CRF and brain opioids is not a 
direct one, since CRF is predominantly produced in the paraventricular nucleus 
while high levels of opioid receptors occur in other areas including the preoptic 
area, the posterior hypothalamus and the locus coeruleus (Bardo, Bhatnagar 
and Gebhart, 1982; Tempel and Zukin, 1987). Furthermore, contradictory 
data has been obtained in man and sheep regarding the nature of opioid 
regulation of the anterior lobe. In man, opioid antagonists have been shown to 
elicit a release of glucocorticoids instead of inhibiting it, and the agonists have 
been shown to cause a suppression of ACTH and glucocorticoid release instead 
of causing a stimulation (Taylor, Dluhy and W illiams, 1983). In sheep, 
Redekopp et al. (1985a) demonstrated an inhibition of ACTH using the 
enkephalin analogue, DAMME, while Wang, Coghlan, Congiu, Scoggins and 
Wintour (1986) showed that met-enkephalin stimulates the secretion of ACTH.
There is experimental evidence that endogenous opioids influence 
the secretory activity of the intermediate lobe of the pituitary gland by acting 
both directly on the melanotrophs and indirectly on hypothalamic DA neurons. 
For example, i.c.v. injection of 8 -END causes a degranulation of melanotrophs
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( Saland, Ortiz & Munger, 1982a), and an elevation of circulating levels of a- 
MSH (De Rotte, Van Wimersma Greidanus, Van Ree, Andringa-Bakker & De 
Weid, 1981; Van Wimersma Greidanus, Van Ree, Goedemans, Van Dam, 
Andringa-Bakker & De Weid, 1981); this is a central effect related to blockade 
of the inhibitory action of DA.(De Rotte et al., 1981). In addition, Celis (1980) 
has shown that 13-END stimulates a-M SH both in vitro and in vivo. 13-END has 
also been shown to antagonize the DA-induced suppression of a-M SH release 
from the intermediate lobe in the frog in vitro ( Saland et al., 1982b). This 
effect could not, however, be observed in the rat (Voigt, Frank, Duker, Martin 
& W uttke, 1983).
Mechanism o f action : In the anterior lobe there are few, if any, opioid receptor 
binding sites in the rat (Lightman, Ninkovic, Hunt and Iversen, 1983), cow 
(Simantov and Snyder, 1977), sheep (Boublik and Clarke, 1984) and monkey 
(W amsley, Zarbin, Young and Kuhar, 1982). The intermediate lobe has 
moderate levels of opioid binding sites (Simantov and Snyder, 1977; Wamsley 
et al., 1982; Lightman et al., 1983; Stojilkovic, Dufan and Catt, 1987). These 
observations point to the fact that the actions of opioids are, primarily, 
centrally mediated. Indeed, high levels of opioid receptors have been found in 
such areas as the medial and lateral preoptic areas, the posterior hypothalamus 
and the locus coeruleus (Bardo et al., 1982; Tempel and Zukin, 1987). Opioid 
receptors are linked to the family of guanine nucleotide regulatory proteins (G- 
proteins) and these proteins have been shown to inhibit adenylate cyclase (Klee, 
Koski, Tocque and Simonds, 1984). Thus, the action of opioids on their 
receptors is not linked to the stimulation of cAMP (Rodbell, 1980; Jakobs, 
Aktories and Schultz, 1984). This action needs sodium ions (Blume, Lichtshtein 
and Boone, 1979), a feature characteristc of horm one systems coupled 
negatively to adenylate cyclase. While the G-mediated inhibition of adenylate 
cyclase remains the best characterized biochemical effect of opioid receptor 
activation, electrophysiological data suggest that alternative mechanisms
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mechanisms account for opioid inhibition in many neuronal systems. Williams, 
Egan and North (1982) showed that opioid-induced hyperpolarization of rat 
locus coeruleus neurons resulted from an increased potassium conductance. 
This led to the suggestion that a G-protein mediates the opioid activation of 
potassium channels in these neurons through a pathway independent of cAMP- 
dependent protein kinase. Opioids action has also been shown to involve an 
inhibition of calcium channels (Werz and Macdonald, 1984; Macdonald and 
Werz, 1986).
All these actions are not in favour of a stimulatory role via CRF and 
would, therefore, indicate that opioids are primarily inhibitory in the 
modulation of B-END secretion from the pituitary gland.
2.5.2 Modulation by gonadal steroids
Scant information is available on the possible influence of gonadal 
steroids on the regulation of B-END secretion from the pituitary gland into the 
peripheral circulation. In male and female rats, a significant reduction in the 
plasm a concentrations of B-END has been observed 3-5 weeks after 
gonadectom y and replacement therapy with testosterone propionate or 
oestradiol benzoate partially restored the plasma levels of B-END, respectively 
(Petraglia, Penalva, Locatelli, Cocchi, Panerai, Genazzani and Muller, 1982). 
In the same study, a decrease in B-END content in the intermediate lobe of rats 
of both sexes was observed. In contrast, Lee, Panerai, Bellabarba and Friesen 
(1980) have reported a decrease in pituitary content of 6 -END after 
gonadectomy in male but not in female rats. Furthermore, it has been reported 
in intact male rats that a 5-day treatment with testosterone propionate had no 
effect on B-END concentrations in either pituitary lobe, whereas a 5-day 
treatment of intact female rats with oestradiol benzoate decreased intermediate 
lobe B-END storage (Mueller, 1980). Thus, there appears to be sex differences
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regarding the effect of gonadal steroids on 8 -END secretion.. There are also 
age differences since old rats have higher B-END contents in both the anterior 
and intermediate lobes in addition to elevated levels in the plasma compared 
with the levels found in young rats (Forman, Sonntag, Hylka and Meites, 1983; 
Missale, Govonis Croce, Bosio, Spano and Trabucchi, 1983). On the other 
hand, significant decreases in plasma concentrations of B-END and B-LPH have 
been described in women with physiological m enopause (Genazzani, 
Facchinetti, Ricci-Danero, Parrini, Petraglia, La Rosa and D'Antona, 1981). 
M echanism o f action : The mechanism of gonadal steroids action on the 
secretion of B-END from the pituitary gland is poorly understood. One 
suggestion is that gonadal steroids act at the level of the pituitary gland to affect 
the processing of B-END from the POMC precursor. This is based on the 
observation that the activity of trypsin-like proteinases which participate in the 
intracellular conversion of precursor hormones into the final product is 
considerably increased in the anterior lobe after gonadectomy (Kenessey, 
Paldi-Haris, Makara and Graf, 1979).
2 A  INFLUENCE OF ENVIRONMENTAL FACTORS
Many environmental factors influence the secretion of B-END, 
apparently acting through stim ulatory and inhibitory system s in the 
hypothalamus (Fig. 1.3). These environmental factors which may influence the 
cycle in B-END secretion include photoperiod and stressful stimuli.
2.6.1 Influence of photoperiod
In seasonal animals such as white-footed mouse, hamster and sheep, 
the secretion of 6 -END into the peripheral circulation is influenced by 
photoperiod. For example, the plasma levels of B-END are markedly increased 
under short days, and decreased under long days (Kumar, Besch, Millard,
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Fig. 2.5. Neural connections conducting light stimuli from the retina in the eye 
to the suprachiasmatic nucleus and then to the pineal gland via the superior 
cervical ganglia. The pineal gland acts as a neuroendocrine transducer, 
converting information regarding the light/dark cycle into a  hormonal signal in 
the form of the 24h rhythm in melatonin secretion. The duration of period of 
melatonin secretion reflects night length and therefore daylength, and this acts 
on the hypothalamo-pituitary axis. RHT= retinohypothalamic tract; SCN= 
suprachiasm atic nucleus; PVN= paraventricular nucleus; SCG= superior 
cervical ganglia.




Sharp and Leadem, 1984; Ebling and Lincoln, 1987; Glass, Ferreira and 
Deaver, 1988). In the Soay ram, there are opposite changes in B-END content 
in the pituitary gland (Ebling and Lincoln, 1987).
Mechanism o f action : The pathway which transmits photic information to the 
hypothalamo-pituitary axis has been thoroughly investigated in the golden 
hamster (Reiter, 1980) as illustrated in Fig 2.5. Light stimulates photoreceptors 
in the retina of the eyes and the photic information is transmitted to the 
suprachiasmatic nucleus of the hypothalamus via a monosynaptic pathway 
known as the retino-hypothalamic tract. From the suprachiasmatic nucleus, the 
photic signal is relayed to the paraventricular nucleus and the pineal gland by 
way of the superior cervical ganglia. A similar photoneuronal pathway is 
evident in sheep (Legan and Winans, 1981; Pau, Kuehl and Jackson, 1982; 
Legan and Karsch, 1983).
The pineal gland acts as a neuroendocrine transducer, converting 
the information regarding the photoperiod into a humoral signal which acts on 
the hypothalamus to influence the secretion of the regulatory peptides and 
neuro-transmitters (Arendt, Symons and Land, 1981; Tamarkin, Baird and 
Almeida, 1985). Although several neuroactive peptides have been identified in 
the pineal gland, considerable evidence points to indolamine, melatonin (N- 
acetyl-5-methoxy-tryptamine), as the active neurohormone that mediates the 
effects of photoperiod.by influencing brain neurotransmitter systems For 
example, treatment with melatonin in the rat has been shown to elevate DA 
levels in the brain (Wendel, Waterburg and Pearce, 1974) as well as to inhibit 
DA release from the hypothalamus (Zisapel, Egozi and Laudon, 1983).The 
observation that melatonin treatm ent inhibits DA release from  the 
hypoyhalamus raises the possibilty that short photoperiods increase B-END 
secretion via the inhibitory action of melatonin on DA release.
The possibility that melatonin may also act directly on anterior lobe 
corticotrophs to influence B-END secretion has been raised by in vitro studies
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in the rat in which melatonin was shown to potentiate the effect of CRF on B- 
END release (Samra, Dechand, Estour, Chalendar, Fevre-Montage, Pugeat and 
Tourniaire, 1985). More recently, the demonstration of melatonin-binding 
sites in the pars tuberalis of the rat and sheep pituitaries further suggests that 
melatonin acts directly on this part of the pituitary gland (Williams and 
M organ, 1988; Morgan, Williams, Davidson, Lawson and Howell, 1989). 
However, the pars tuberalis contains cells which are morphologically different 
from those of the rest of the anterior pituitary and may not be involved in the 
secretion of B-END.
2.6.2 Influence of stressful stimuli
The influence of acute stressful stimuli on B-END secretion into the 
peripheral circulation has been demonstrated in a number of studies involving a 
variety of acute stressful stimuli. For example, in rats, elevated plasma levels of 
B-END have been observed following footshock (Rossier, French, Rivier, 
Ling, Guillemin and Bloom, 1977a) and restraint stress (De Souza and Van 
Loon, 1985). In sheep plasma levels of B-END have been elevated in response 
to acute haemorrhage (Smith, Owens, Lovelock, Chan and Falconer, 1986), 
electroimmobilization and shearing (Jephcott, McMillen and Rushen, 1987). 
There is also an increase in B-END secretion in response to hypoglycaemia and 
audiovisual stimulus (barking dog) (Engler et al., 1988) and during handling, 
transport and slaughter (Fordham, Lincoln, Ssewannyana and Rodway, 1989). 
Increases in plasma levels of B-END and related peptides have also been 
demonstrated in other species, including man, following various acute stressful 
stimuli (Nakao et al., 1979; for reviews see Antoni, 1986; Smith and Funder,
1988).
Chronic stress has also been shown to affect B-END secretion. For 
example, in rats, daily footshock for 14 days increases the content of ACTH and 
8 -END in the anterior lobe of the pituitary gland (Young and Akil, 1985).
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A fterl4  days, the animals develop tolerance, indicating adaptation to the 
chronic stress. In a seasonal environment where extreme cold and food 
deprivation in winter may constitute chronic stress to the animal, such 
adaptation occurs. Of particular interest to this thesis are data obtained by 
exposing rats to an environment of a cold room, with marked hypothermia 
mimicking the effects of hibernation. In these circumstances, there was a 
decrease in the plasma levels of ACTH (Gibbs, 1985); the decrease was 
apparently due to a decline in AVP levels in pituitary portal blood as there was 
no change in the portal blood concentrations of CRF (Gibbs, 1985). With 
respect to the seasonal cycle in B-END secretion, this might suggest that the low 
levels of B-END seen in winter occur as a result of a decrease in the drive from 
the hypothalamus.
M echanism o f action : The stress-induced release of B-END is associated with 
the activation of the paraventricular hypothalamus to release CRF, AVP, 
oxytocin and NE (Plotsky, Bruhn and Vale, 1985; Antoni, 1986). Flowever, the 
type of factor(s) released from the hypothalamus depends on the type of 
stimulus. For example, ether stress, haemorrhage and insulin-induced 
hypoglycaemia involve the release of CRF, AVP, oxytocin and NE into the 
hypophysial portal blood (Rivier and Vale, 1983b; Bruhn, Plotsky and Vale, 
1984a; Mezey, Reisine, Brownstein, Palkovits and Axelrod, 1984; Plotsky et 
al., 1985); formalin and immobilization stress involve the release of CRF and 
AVP only (Linton, Tilders, Hodgkinson, Berkenbosch, Vermes and Lowry, 
1985; Nakane, Andhya, Kaine and Hollander, 1985); and hypothermia seems to 
involve the release of AVP and oxytocin only (Gibbs, 1985). W hether this 
means that the hypophysiotrophic signal to a given stressful stimulus originates 
from several groups of anatomically distinct neurons (e.g. parvicellular CRF, 
magnocellular AVP and oxytocin neurons) remains to be investigated. The 
possible involvement of peripheral catecholamines in mediating the actions of
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stress as CRF stimuli is still a matter of controversy (Cryer, Gerich, Dallman, 
Greer, Reisine, Mezey, Palkovits, Brownstein and Axelrod, 1986).
The effect of stressful stimuli on the hypothalamic systems 
controlling the release of CRF and AVP results in changes in the synthesis and 
release of 13-END from its precursor, POMC. There is evidence that both acute 
and chronic stress may modulate posttranslational processing of POMC and the 
release of 6 -END and ACTH. Shiomi, Watson, Kelsey and Akil (1986) have 
demonstrated that, after an acute footshock stress in the rat, the rate of POMC 
translation is increased by 50%, and the rate of conversion to immunoreactive 
products is doubled. In the same study, when the animals were subjected to 
chronic stress, the 6 -END/ACTH stores in the pituitary gland were increased, 
presumably due to an increase in transcription and POMC mRNA levels; 
however continued stress did not affect posttranslational processing. 
Furthermore, Hollt, Przewlocki, Haarmann, Almeida, Kley, Millan and Herz
(1986), using an intermittent electrical footshock stress, saw an approximately 
2-fold increase in POMC mRNA levels in the anterior lobe after 3 days of 
treatment and the levels remained elevated after 7 days of treatment; however, 
there were no significant differences in the intermediate lobe POMC mRNA 
levels. On the other hand, Dave, Eiden, Karanian and Eskay (1986) have 
demonstrated that POMC gene expression is inhibited in both the anterior and 
intermediate lobes by chronic exposure to ethanol stress. If the extreme cold 
and food deprivation that occur during winter are interpreted as chronic stress 
leading to adaptation in the animal's physiology, then the synthesis and 
processing of the POMC precursor may be inhibited with a resultant decrease 
in 6 -END secretion, partially accounting for the low levels of 6 -END that 
occur in winter.
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2.7 PHYSIOLOGICAL SIGNIFICANCE OF 6 -END
6 -END is widely distributed throughout the body (section 2.2); such 
a wide distribution is suggestive of a broad spectrum of target tissues whose 
function is regulated or modified by this peptide. It may have endocrine actions 
centrally on the brain or peripherally on target tissues or may have paracrine 
actions adjacent to its site of release.
2.7.1 Actions on the brain
The simplest evidence in support of an action of 6 -END on brain 
function is the capacity of systemically administered 6 -END, in both animal 
and clinical studies, to modify both endocrine and behavioural parameters 
integrated in higher centres of the brain (Millan and Herz, 1985); indeed, 
parenterally administered 6 -END has been shown to cross the blood brain 
barrier (Merin, Hollt, Prezewlochi and Herz, 1980; Rapoport, Klee, Pettigrew 
and Ohno, 1980; Gerner, Sharp and Catlin, 1982; Ohlsson, Tsu-Ching, Jones, 
M artin and Dewley, 1982). 6 -END, via the systemic circulation, may also 
interact with brain opioid receptors located externally of the blood brain 
barrier, for example, the subfornical organ and area postrema which lie in 
close proximity to autonomic regulatory centres in the hypothalamus and the 
brain stem, respectively (Millan and Herz, 1985). Furthermore, the median 
eminence and mediobasal-arcuate hypothalamus possess opioid receptors, 
whose activation by central or circulating 6 -END may be involved in 
endocrine regulation by affecting the release of pituitary hormones. For 
example, the i.c.v. injection of 6 -END suppresses the release of GnRH from 
hypothalam ic neurons, resulting in a decrease in LH secretion (Schulz, 
W ilhelm, Pirke, Gramsch and Herz, 1981; Kalra and Kalra, 1983) and the 
introduction of antisera against 6 -END into the mediobasal hypothalamus of 
immature female rats causes an increase in the plasma levels of LH (Schulz et
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al., 1981). 6 -END may also have antiovulatory effects via its suppressive action 
on hypothalamic GnRH. In female rats there is a proestrus surge of LH which 
underlies the initiation of ovulation. B-END administered during the critical 
period of proestrus may prevent the occurrence of ovulation by interfering 
with the requisite LH surge based on the results obtained with morphine and 
naloxone (Pang, Zimmerman and Sawyer, 1977; Ieiri, Chen, Campbell and 
Meites, 1980). Furthermore, a clinical finding is the abnormally high incidence 
of relative infertility, for example, in heroin addicts, which may partially 
reflect a disruption of LH control (Meites, Bruni, Van Vugt and Smith, 1979).
Other pituitary hormones whose secretion is influenced by the 
action of 6 -END on the brain are PRL, growth hormone and TSH. In the brain, 
6 -END interacts with DA to influence PRL secretion. Administration of 6 - 
END i.c.v. or intracistemally increases the plasma levels of PRL and decreases 
hypophysial portal levels of DA (Grandison and Guidotti, 1977a; Rivier, Vale, 
Ling, Brown and Guillemin, 1977; Van Loon et al., 1980a,b,c). In addition, 
the i.c.v. administration of antisera against 6 -END suppresses basal levels of 
PRL in the circulation and attenuates the stress-elicited release of PRL, 
suggesting a role for 6 -END in the control of PRL secretion (Ragavan and 
Frantz, 1981). 6 -END injected i.v. or intracistemally has also been shown to be 
a potent stimulant of growth hormone (Rivier et al., 1977). 6 -END has also 
been implicated in the modulation of thyroid stimulating hormone in man but 
not in the rat (Grossman, Stubbs, Gaillard, Delitala, Rees and Besser, 1981; 
Grossman et al., 1982), which suggests that 6 -END is involved in metabolism.
2.7.2 Actions in the periphery
It is possible that 6 -END may act locally in a paracrine way to 
influence the function of the tissues that produce it, or it may act in a 
conventional hormone-like fashion to activate receptors located in remote 
tissues. 6 -END is locally produced in the gut and it may be involved in food
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digestion, based on the evidence that naloxone reduces the secretion of gastric 
acid and gastric acid secretory response in man (Feldman, Walsh and Taylor, 
1980). In addition, solutions of low pH have been shown to release B-END in 
vitro together with secretin, motilin and vasoactive intestinal peptide from 
duodenal mucosa in man (Matsumura, Saito and Fujino, 1982a, Matsumura et 
al., 1982b). B-END is also involved in the regulation of pancreatic secretion. 
Infusion of B-END in dogs elevates the plasma levels of glucagon and results in 
a transient hypoglycaemia (El-Tayeb, Gauthier, Brubaker, Lickley and Vranic,
1986), while the i.v. injection of B-END in rabbits causes hypoinsulinaemia and 
hyperglycaemia (Knudtzon, 1986). B-END has also been shown to stimulate the 
secretion of insulin and glucagon in humans (Reid and Yen, 1981). Of special 
note are data which show that B-END can bind and/or modify the activity of 
adipocytes and also facilitate corticosterone formation in the adrenal cortex 
(Millan and Herz, 1985). These observations further highlight the view that B- 
END is involved in carbohydrate and fat metabolism.
B-END is also involved in the regulation of respiratory and 
cardiovascular functions. For axample, i.v. injection of B-END results in 
bradycardia and hypotension (Lemaire, Tseng and Lemaire, 1978). Blood 
vessels and blood cells are also targets of circulating B-END. This peptide has 
been shown to cause vasodilatation of the microcirculatory system of hamster 
cheek pouch (Wong, Koo and Li, 1981) and to modify the activity of blood 
platelets, human complement, leucocytes, lymphocytes and monocytes, 
consonant with its role in the regulation of the immune system (Smith and 
Blalock, 1981; Gilman, Schwartz, Milner, Bloom and Feldman, 1982; Johnson, 
Smith, Torres and Blalock, 1982). It is interesting to note that the action of 6 - 
END on human complement and lymphocytes is through the carboxy-terminus 
rather than the amino-terminus, which is involved in binding to opioid 
receptors (Gilman et al., 1982; Mehrishi and Mills, 1983; Schweigerer, Bhakdi 
and Teschemacher, 1982). It is conceivable that the binding of B-END to
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complement is of special physiological relevance in the adaptation of the 
immune system to stress.
8 -END produced in the testis has been shown to act as a paracrine 
inhibitor of Sertoli cell function in cell cultures. Chronic 8 -END treatment of 
Sertoli cells of immature and adult rat testes in culture significantly inhibited 
basal and FSH-stimulated androgen-binding protein production; this effect 
being prevented by the opioid antagonist, naloxone (Fabbri and Dufau, 1988). 
Furthermore, the production of 8 -END in the follicular cells of the ovary may 
be related to the oestrous cycle, perhaps affecting maturation or transportation 
of the oocytes. This is based on the observation that significantly higher 
concentrations of 8 -END are found in ovaries removed in the periovulatory 
period than in those removed from anoestrous ewes (Lim et al., 1983), and also 
on the observation that high 6 -END immunoreactivity is seen in corona radiata 
and cumulus oophorus cells of ovulated oocytes (Shaha et al., 1984).
Functional signi ficance o f circulating B-END in seasonal animals: The timing 
of the seasonal changes in 6 -END secretion are associated with the changes in 
the reproductive axis, body growth and fattening. In the hamster, the plasma 
levels of 6 -END are high under short days when the animals are sexually 
inactive and are low under long days when the animals are sexually active 
(Kumar et al., 1984); on the other hand, in sheep, the plasma levels of 8 -END 
are high under short days when the animals are sexually active and are low 
under long days when the animals are sexually inactive (Ebling and Lincoln, 
1987). Thus, there is no consistent relationship between the cycle in peripheral 
secretion of 8 -END and the cycle in reproduction for different species.
The timing of the seasonal changes in 8 -END secretion observed in 
the Soay ram is positively correlated with the seasonal changes in body growth 
and fattening (Ebling and Lincoln, 1987). A positive correlation between 
cortisol secretion, body growth and fat deposition has also been observed in the 
Svalbard and Norwegian reindeer (Larsen, Nilsson and Blix, 1985; Nilssen,
42.
Bye, Sundsfjord and Blix, 1985). These observations imply that B-END is 
involved in body growth and fat deposition in autumn as part of the adaptations 
to survive during the period of food deprivation in winter.
Three lines of evidence support the view that B-END plays an 
important role in the regulation of metabolism. Firstly, B-END is released with 
ACTH from the anterior lobe of the pituitary gland. Since these peptides are 
generated together they may act together to coordinate functions in the 
periphery. ACTH is involved in metabolism by its stimulatory effect on the 
adrenal cortex to produce glucocorticoids which play an important role in the 
regulation of protein, carbohydrate and fat metabolism. B-END also appears to 
play a role in the control of metabolism. For example, infusion of B-END in 
the carotid artery and jugular vein of dogs has been shown to cause increases in 
glucagon and cortisol levels and a transient decrease in plasma glucose 
concentrations (El-Tayeb et a l ,  1986). Secondly, it has been observed that 
animals with abnormalities in carbohydrate and fat metabolism, for example 
congenitally obese rats and mice, have high circulating levels of B-END 
(Margules, Moisset, Lewis, Shibuya and Pert, 1978; Govoni and Yang, 1981). 
Thirdly, elevated plasma levels of 8 -END are positively correlated with body 
weight in obese women (Givens, Wiedemann, Anderson and Kitabchi, 1980).
Thus, in seasonal animals like the Soay sheep, the most likely role of 
B-END is to regulate body resources and energy in such a way that the animals 
eat more and accumulate fat in summer and autumn in anticipation of food 
restriction associated with winter.
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CHAPTER 3 




Rams of the Soay breed of sheep illustrated in Fig. 1.1 were used in 
the majority of the studies described in this thesis. The animals were obtained as 
yearlings from commercial farms (Mr. P. Mapson, Cambridgeshire and Dr. G. 
A. Lincoln, Fife). Some of the rams were kept outdoors while others were kept 
indoors.
Outdoor groups : Groups of eight to sixteen rams were kept outside in grass 
paddocks at Dry den Field Station of the Institute of Animal Physiology and 
Genetics near Edinburgh ( 56°N ). These animals were kept as all-male groups 
and were provided with an indoor shelter and fed a supplement diet of hay and 
sheep nuts during winter (Table 3.1).
Indoor groups : Groups of five to eighteen rams were kept permanently 
indoors in light controlled rooms at the Marshall Building of the University of 
Edinburgh, Roslin. (Table 3.1). The rams were penned individually within 
visual and olfactory contact and were fed a diet of grass pellets and hay, and 
water was available ad libitum. Artificial daylight was provided by fluorescent 
strip lights (4 x 180 cm) with light intensity of 300-400 lux at the ram's eye 
level, and lights on and off were controlled by time clocks ( Sangamo Western 
Ltd, Port, Glasgow, U. K.). The rams were normally exposed to an artificial 
lighting regimen of alternating 16-week periods of long days ( 16h light : 8 h 
darkness, 16L : 8D ) or short days ( 8L : 16D ) which entrained the animals' 
physiological cycles to a period of 32 weeks (Ebling & Lincoln, 1987). In 
experiment 6 the rams were exposed to a lighting regimen of 30 weeks of long 
days followed by 10 weeks of short days; then 16 weeks of alternating long and 
short days, and finally to 14 weeks of long days. Changes from one
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Table 3.1 Animal groups used in the studies described in this thesis
Outdoor rams Experiments
12 Soay rams 1, 8 ,9 ,10 ,11  and 13
7 Tasmanian Merino and 4 crossbred rams 2
8 Soay rams: 3 controls and 5 PINX 3
16 Soay rams: 8 controls and 8 melatonin-
implanted 4
Indoor rams Experiments
7 Soay rams 5
8 Soay rams: 4 controls and 4 melatonin- 
implanted 6
18 Soay rams: 6  controls, 6 castrates and
6  castrates + testosterone implants 7
5-8 Soay rams 12,14,15,16,17 and 18.
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photoperiod to another were made by altering the time of lights off. The 
temperature in the rooms was maintained relatively constant by supplementary 
heating in winter months (daily mean ± SEM, 15.3 ± 0.3).
3.1.2 Other rams
A secondary study was also conducted on seven Tasmanian Merino
rams obtained from the AFRC Institute of Animal Physiology and Genetics 
Research, Edinburgh, and four crossbred rams produced locally by mating one 
Tasmanian Merino ram with ten Soay ewes (Table 3.1). These rams were kept 
outside as all-male groups in grass paddocks at the Dryden field station.
3.2 BLOOD SAMPLING AND ROUTINE MEASUREMENTS
3.2.1 Outdoor rams
Routine 10 ml blood samples for hormone assays were collected 
every w eek by jugular venepuncture, using heparinized plastic tubes 
(Brunswick) and a plastic syringe (Plastipak) fitted with a 21G needle. For this, 
the rams were herded by a sheep dog into a pen in the field and allowed to rest 
for l - 2 h before blood sampling; each ram  was handled with minimum 
disturbance during blood sampling. Body weight and testis diameter were 
recorded every 2  weeks; whenever this was done, routine blood samples were 
collected before this procedure.
For the collection of serial blood samples at 10 or 15 min intervals, 
the rams were moved into pens and then transferred to crates on the day before 
the study. A polythene cannula (Braunula Luer, Armour Pharmaceuticals) was 
inserted into the jugular vein of each ram and was anchored to the skin of the 
neck with silk sutures (Ethicon). The cannula was connected to a three-way tap 
(Vygon-VGl) by a 60 cm polythene tube ( Portex ) and kept patent with 0.9% 
physiological saline (w/v; Travenol Labs.) containing 10,000 I. U. heparin /
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litre (Wellcome Diagnostics). Blood samples were collected into 5ml plastic 
syringes (Plastipak) and transferred to heparinized plastic tubes.
3.2.2 Indoor rams
Routine 10 ml blood samples were collected every week as for 
outdoor rams. For serial blood samples at 10 or 15 min, the rams remained in 
their home pens and were cannulated a day before the study as for the outdoor 
rams.
In all cases, care was taken not to disturb the animals during blood 
sampling; the blood samples were collected on ice and centrifuged within 30-40 
min for 30 min at 2500rpm. Plasma was removed and stored in 5 or 10 ml vials 
(Sardstedt) at 20°C until required for assay. In instances where B-END and 
ACTH were to be measured in the same blood sample, the plasma was divided 
into two aliquots to avoid repeated thawing.
3.3 DRUGS AND SOLVENTS
A VP was purchased as a 10 I. U./ml solution from Sigma Chemical 
Company (Poole, Dorset, U. K.); CRF (Amunine, ovine 1-41), B-END (human 
B-LPH, 61-91) and ACTH (human, 1-24) were obtained from Bachem UK Ltd 
(Saffron, Walden, Essex, U. K.). CRF was dissolved in 0.003N HCL and both 
B-END and ACTH were dissolved in 0.9% physiological saline ( w/v ) obtained 
from Travenol Labs. Ltd (Thatford, Norfolk, U. K.). DEX was obtained as a 
4mg/ml solution of dexamethasone sodium sulphate from M erck Sharp & 
Dohme (MSD) Ltd (Hoddesdon, Herts, U. K.); RU 486 was kindly donated by 
Roussel-Uclaf ( Paris, France ) and was dissolved in 50% ethanol : propylene 
glycol ( v/v ); NAL was kindly donated by Sterling-W inthrop ( Surbiton, 
Surrey, U. K. ); DA was purchased from Sigma Chemical Company (Poole, 
Dorset, U. K.). Both NAL and DA were dissolved in physiological saline.
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Bromocriptine and sulpiride were kindly donated by Drs. J. Curlewis and A. S. 
McNeilly ( MRC Reproductive Biology Unit, Edinburgh ) and were dissolved 
in 15% ethanol ( v/v ) and 0.01N NaOH, respectively. Bromocriptine was 
originally obtained from Sandoz Products Ltd (Feltham, Middlesex, U. K) and 
sulpiride was originally obtained from Delagrange ( Paris, France). Heparin 
was purchased as a 25,000 I. U./ml solution from Leo Labs. Ltd (Risborough, 




Plasma concentrations of 13-END were measured in unextracted 
plasma by radioimmunoassay based on the assay described and validated for 
ovine plasma by Leshin and Malven (1984). The 13-END assay was always the 
first assay to be done on those samples collected for the measurement of several 
hormones.
Although the 8 -END assay had been validated for unextracted ovine 
plasma, the effect of plasma was still checked as follows: (i) a portion of a pool 
of plasma from hypophysectomized sheep, provided by Dr. A. McNeilly 
( MRC Reproductive Biology Unit, Edinburgh ) was assayed after extraction to 
confirm that there was no 8 -END detectable in it. No 8 -END was detected in 
the hypophysectomized plasma by this assay with a sensitivity of 24.40 pg/ml;
(ii) standard 8 -END (camel 8 -END i . 3 1 ; 0.2 to 12.5 ng/ml) was added to two 
portions of the hypohysectomized plasma. One of these portions was extracted, 
reconstituted in buffer and assayed; the other portion was assayed directly. 
Recoveries of standard 8 -END were 88.3 ± 4.9 % and 91.4 ± 7.8 % for direct 
and extraction assays respectively; (iii) two pools of whole plasma were used. 
One portion of each pool was extracted before assay and the other was assayed
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directly. There was good agreement between estimates of 6 -END concentration 
in whole plasma and in extracts of plasma ( Table 3 .2 ).
Taken together, these results indicate that the assay of whole ovine 
plasm a or extracts of plasm a will yield similar estim ates of B-END 
concentration. The assay of unextracted plasma is preferred because it does not 
introduce potential errors of differential extraction and elution from silica 
grass or silicic acid, and it is more adapted to the large numbers of samples 
which neuroendocrine studies involve.
Leshin and Malven (1984) observed that incubation of 125i_g_END 
with plasma under assay conditions resulted in the appearance of a labelled 
product of smaller molecular weight (1400 dal tons) than B-END ( molecular 
weight = 3439 ). Approximately one-half of this small molecular weight 
product was bound and was displaced from the B-END antiserum. They 
hypothesized that this condition may be a prerequisite for a valid B-END RIA 
for whole plasma. However, they noted that the ratio of this product to intact 
125i _6_e n d  averaged only 0.29 ± 0.08 ( n = 10 ) and that the generation of this 
small molecular weight product varied widely among different plasma pools. A 
test of the occurrence of this product was carried out on five pools of plasma 
following the method of Leshin and Malven ( 1984 ). No such small molecular 
weight product was observed.
Because B-LPH exists in ovine plasma and since this RIA for 
B-END is using an antiserum which cross-reacts about 30 % by weight with 
B-LPH ( Ebling & Lincoln, 1987 ), the estimates of B-END should be assumed 
to contain a contribution from the endogenous B-LPH. However, the ratio of 
B-LPH to 6 -END in the plasma of the Soay ram is low (B-LPH : B-END, 1 : 7.7 
under short days; 1 : 3.4 under long days; Ebling and Lincoln, 1987).
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Table 3.2. Comparison of radioimmunoassay of unextracted ovine plasma with 
that of extracted ovine plasma. Values are means ± SEM (pg/ml), n=12 
determinations in duplicate per pool for each method.
RIA of unextracted plasma RIA of extracted plasma
Pool 1 560.02 ±14.42 540.69 ±31.90
Pool 2 580.76 ± 23.15 620.45 ± 26.32
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3.4.1.] Reagents
Buffer  : The standard buffer contained 0.25 % ( w/v ) bovine serum albumin 
(RIA grade, Sigma ) and 0.2 % ( w/v ) sodium azide ( BDH, Poole ) in 0.05M 
PO4  buffered saline ( pH 7.6). For assays, 0.1 % ( v/v ) a-2-mercaptoethanol 
( Sigma ) was added to the standard buffer as a preservative and two drops of 
phenol red indicator ( Flow L abs.) were also added to monitor the pH.
Standards : Camel B-ENDi-31  ( S igm a) was used for preparation of standards 
and for iodination. The structure of camel B-END 1 .31  and ovine B-ENDi-31 
are identical ( Li & Chung, 1976 ). Solid peptide was dissolved in 0.01 N HC1 to 
give a 0.5 p.g/|il stock solution. 10 jxl ( = 5 pLg ) aliquots were pipetted into 
plastic stoppered LP3 tubes ( Sardstedt ) and stored at -400c  for use as 
iodination aliquots.
For assay standards, a 10 (il aliquot was further diluted with 
standard buffer to give a 50 ng/ml solution. 1 ml aliquots of this solution were 
pipetted into plastic stoppered LP3 tubes ( Sardstedt) and stored at -400c for 
up to one year.
Antiserum  : The antiserum 7.9.02 used in these studies was raised in Soay rams 
at the MRC Reproductive Biology Unit in Edinburgh against the synthetic 
ovine B-END conjugated to porcine thyroglobulin with carbodiimide (Ebling 
& Lincoln, 1987). In the assays it was used at a final dilution of 1 : 99,600 
which gave 50 % inhibition of specific binding of 100-120 pg/tube. This 
antiserum has negligible cross-reaction with a -E N D i-1 7  (<  0.19 % ), 
y-ENDi-16 (< 0.19 %), met-enkephalin (<  0 .001  % ), dynorphini-1 7  
(< 0.05 %) and A CTH i-3 9  ( < 0.11 % ). However, it crossreacts 100% with 
B-LPHi-91 (Ebling and Lincoln, 1987). In the Soay ram B-LPHi-91  has been 
previously shown to be present in low concentrations compared with B-END
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(Ebling and Lincoln, 1987). Thus, the hormone concentrations measured by 
this assay are assumed to be predominantly 6 -END.
Quality controls : Three plasma quality controls, low (500-750 pg/ml), medium 
(800-1000 pg/ml) and high (1200-1800 pg/ml) were included in each assay. 
The low and high quality controls were prepared by taking a pool of blood 
plasma from outdoor Soay rams in winter (low plasma levels of 6 -END) and in 
summer (high plasma levels of 6 -END), respectively. A portion of the low 
quality control plasma and a portion of the high quality control plasma were 
mixed to produce the medium quality control plasma. The three quality 
controls were used to calculate the within and between assay C. Vs.; this was 
done by the Assay Zap computer program designed to calculate the assay 
results. The average intra- and inter-assay C. Vs. for the assay were 5.6% and 
1 1 .2 %, respectively, based on 288 assays.
13-END tracer : The chloramine T method of iodination was used to produce the 
tracer. A working solution of 10 mg in 10 pi 0.05M PO4  buffer was prepared 
just prior to use. To the iodination aliquot of 6 -END (5 pg) was added:
10 pi 0.25M PO4  buffer (no bovine serum albumin or preservative)
10 pi Na 125i  (specific activity -15mCi/pg iodine, Amersham)
10 pi working solution of chloramine T (= 10 pg)
The mixture was allowed to react for 30 seconds then was diluted 
with 1 ml assay buffer, counted and immediately loaded onto a prepared Sep- 
Pak C l 8 column (Waters Assoc., MA, U. S. A). The column was prepared by 
washing it with 3 X I ml 80% m ethanol : water containing 1% (v/v) 
trifluoroacetic acid (Sigma), then with 3 X I ml 1% trifluoroacetic acid alone.
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The reaction mixture was eluted with a stepped increasing gradient 
of methanol. The initial wash was with 1 ml 0.25M PO4  buffer, then 1 ml 
m ethanol: water at concentrations of 30%, 40%, 50%, 60%, two X 65%, six X 
70% and six X 80% (Fig. 3.3). All washes contained 1% trifluoroacetic acid 
and the eluate was collected in plastic LP3 tubes. The appropriate fractions 
were made up to 5 ml with 70% m ethanol: water and were stored liquid at 
-20°C for 4 weeks.
For assay and record purposes, the approximate specific activity of 
the tracer was calculated as follows, assuming that all the 5 |i.g of the iodination 
aliquot was in the column fractions counted:
volume of N al25j taken = 10 |il containing 1000 }iCi
total counts = 14877
counts as B-END = 12391
% iodination yield = counts as B-END/ total counts X 100 = 12391/14877 X
= 83.6%
radioactivity incorporated into protein = % iodination yield/100 X original 
activity
= 83.6/100 X 1000= 835.71 |_tCi 
specific activity = protein radioactivity/weight of protein = 835.71/5
= 167(iCi/(ig
Dextran-charcoal suspension : Because the B-END antiserum 7.9.02 was raised 
in Soay rams and the measurements of plasma concentrations of B-END were 
made in the same animals, the dextran-charcoal method of M cLoughlin,
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Fig. 3.3. E lu tion  profile of 125i-Sc-endorphin tracer from  a Sep-Pak C l8 
column. The column was first loaded with the iodination mixture, then washed 
with 0.25M PO 4 buffer followed by washes with 30%, 40%, 50%, 60%, 2  X 
65%, 6 X  70%  and 6 X 80% methanol: water.
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Lowry, Ratter, Besser & Rees (1980 ) was used to separate the bound from the 
free tracer. The dextran-charcoal suspension was prepared by first dissolving 
0.75g Dextran T70 ( Pharmacia ) in 40 ml 0.05M P 0 4  buffer, then adding 10 
ml normal sheep serum ( Scottish Antibody Production U n it) and 3g charcoal 
(C-5260, Sigma). The suspension was stirred for 45-60 min in an ice bath 
before adding it to assay tubes.
3.4.1.2 Design
A standard curve with serial dilutions of standard 6 -END from 
2500 pg/tube to 4.88 pg/tube was set up in ten pairs of plastic LP3 tubes, being 
preceded by three pairs of tubes for total counts, non-specific binding and zero 
binding. Three more pairs of tubes were set up for three plasma quality 
controls : high (200-300 pg/tube), medium (140-180 pg/tube) and low (60-100 
pg/tube); these were followed by tubes for the unknown samples.
3.4.1.3 Procedure
On day 1, duplicate 200 |il of standard or unknown sample were 
dispensed into plastic LP3 tubes using a microlab (Hamilton Bonaduz AG); then 
the 8 -END antiserum was added at a dilution of 1 : 16,600 in 50 |il assay buffer. 
After thorough mixing, the tubes were covered and incubated at 4°C for 24h. 
Incubation of antiserum with standard (or unknown) for NOT less than 24h is a 
critical requirement to reliably detect the small quantities of standard 8 -END 
(or unknown samples under long days). On day 2, 10-12,000 counts per min of 
125i_g_I3ND was added in 50 |il assay buffer. The tubes were vortexed, 
covered and incubated at 4°C for another 20-24h. On day 3, 250 |il of the cold 
dextran-charcoal suspension was added to separate the bound from the free 
hormone. The tubes were then vortexed, centrifuged at 2500 rpm at 4°C for 20 
min. The supernatant (containing the bound hormone) was tipped into clean
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Fig. 3.5. Recovery of 8c-endorphin standard added to 3ml of plasma as a 
proportion of the initial amount added.
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LP3 tubes and counted using a NE 1600 gamma counter (Nuclear Enterprises, 
Edinburgh).
3.4.1.4 Calculation o f assay results
Raw counts were processed by an Assay Zap program developed 
for Apple Macintosh microcomputer by Dr. P. L. Taylor (MRC Reproductive 
Biology Unit, Edinburgh). This program draws a standard curve, calculates the 
total binding for the assay, the quality controls along with the consequent 
within- and between-assay C. V. plus the calculation of the concentration of 
unknown samples. An example of a standard curve drawn by this program is 
shown in Fig. 3.4.
3.4.1.5 Extraction o f 6-END from plasma
For the comparisons made in section 3.4.1, 6 -END was extracted 
from plasma according to the procedure described by Ebling and Lincoln 
(1987). The extraction efficiency for this procedure was tested and found to be 
75.8 ± 2.76%, mean ± SEM (Fig. 3.5).
3.4.2 Nac-G-END assay
The conventional radioimmunoassay for measuring total 6 -END 
was modified to measure Nac-6 -END by using human Nac-G-END i -31 instead 
of camel 6 -END 1 -31 for standards and iodination. The radioimmunoassay for 
measuring Nac-G-END employed an antiserum ( R l-5 ) specific for Nac- 
G-END kindly donated by Dr. E. W eber, Stanford University School of 
Medicine, California, U. S. A. The cross-reactivity of this antiserum with 
camel G-END was 0.17% based on the amount of unlabelled peptide needed to 













































































The plasma concentrations of ACTH were measured in duplicate by 
the immunoradiometric assay described by Hodgkinson, Allolio, Landon and 
Lowry ( 1984 ). In this assay, 0.05M PO 4  buffer was used at pH 7.4 and 
A C T H  1 -3 9  was used as standard made in a base of horse serum. 
Radioiodination of sheep anti-ACTH immunoglobulin was carried out by a 
m odification  of the Iodogen m ethod. Iodogen, in a solution of 
dichloromethane, was put in a polypropylene vial, and then the solvent was 
evaporated. To the vial, 0.5M PO4  buffer, sheep anti-ACTH IgG and sodium 
125i were added in order. After reaction, the vial contents were transferred to
0.05M PO 4  buffer and the mixture was applied to a column. A single major 
peak of radioactivity was eluted and to this was added 1% mannitol and 10% 
normal sheep serum. The tracer was then kept frozen at -20°C.
The assay procedure was of the "simultaneous addition" variety. To 
200 |il of sample was added anti-ACTH IgG and rabbit anti-ACTH antibody 
(anti-ACTH {34-39} peptide or anti-ACTH {2-16} peptide) in 0.05M PO4  
buffer. These were incubated overnight at room temperature. Separation of 
ACTH-bound from free labelled antibody was achieved by precipitation of the 
bound complex using sheep anti-rabbit second antiboby. Then, the tubes were 
incubated for 30 min at room temperature and were centrifuged for 30 min 
after the addition of 1 ml of 2% polyethylene glycol solution in 0.05M PO4  
buffer. The soluble free fraction was aspirated to waste and the precipitated 
hormone counted. The sensitivity of the assay was 10 pg/ml and the intra-and 
inter-assay C. V. for duplicates of quality control pools of horse serum " spiked 




The plasma concentrations of cortisol were measured in duplicate 
by radioimmunoassay using the method of Abraham, Buster and Teller (1972), 
as modified by Hillier and Read ( 1975 ) and Hunter, Nars and Ruthersord 
(1975) for an iodinated tracer. In this assay, 0.1M P04-gelatin buffered saline 
(PGBS) was used as buffer and synthetic cortisol ( Sigma ) was used for 
standard. Cortisol antiserum S004-201 (Scottish Antibody Production Unit) 
was used at a final dilution of 1 : 24,000. The tracer was prepared by 
Chloramine T method; this involved reacting 125^  cortisol-histam ine 
conjugate and chloramine T. The reaction was terminated by the addition of 
sodium metabisulphite and the labelled cortisol was extracted with ethyl 
acetate. A fter separation, the steroid fraction was run on a thin-layer- 
chromatographic plate. Then, the radioactive peak was transferred and stored 
in ethanol at 4°C.
The samples (50 ¡il) were extracted in 1 ml dichloromethane and 
dried down under nitrogen in a heating block at 40°C . The extract was 
reconstituted in 200 ¡il of 0.1M PGBS. To 100 p.1 of the reconstituted extract 
was added 100 |il of antiserum, and then 100 jil of tracer was added. The tubes 
were mixed and incubated overnight at 4°C before separating the bound from 
the free hormone by the dextran-charcoal method. The supernatant, containing 
the bound hormone, was then counted. The lower limit of detection of the assay 
was 2.3 ng/ml. The mean intra- and inter-assay C. V. were 5.5% and 7.8% 
respectively, based on 10 assays.
3.4.5 PRL assay
The plasma concentrations of PRL were measured in duplicate by 
RIA described by McNeilly and Andrews (1974). The buffer used for this
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assay consisted of 1% bovine serum albumin/phosphate (BSA/PBS) (w/v) and 
the reference standard was NIH-P-S9 (NIAMDD, Bethesda, U. S. A.). The 
antiserum R50 was used at a final dilution of 1 : 422,400. The tracer was 
prepared by the Lactoperoxidase method; this involved reacting 125^ 0vine 
PRL, lactoperoxidase and hydrogen peroxide. The reaction was terminated by 
1 ml of 0.1% BSA/PBS, then the reaction mixture was loaded onto a column. 
After separation, the reactive peak was kept frozen at -20°C.
The assay procedure involved taking 30 pi of sample to which was 
added 100 pi of buffer, 100 pi of first antibody and 100 pi of tracer. The 
mixture was then incubated overnight at 4°C. On the second day, 200 pi of 
second antibody was added and the tubes were again incubated overnight at 
4°C. On the third day, the tubes were spun, the supernatant discarded and the 
precipitate counted. The lower limit of detection of the assay was 0.4 ng/ml. 
The mean intra- and inter-assay C. V. were 8.3% and 11.9% respectively, 
based on 78 assays.
3.4.6 Testosterone assay
The plasma concentrations of testosterone were measured in 
duplicate by radioimmunoassay using the method described by Corker and 
Davidson ( 1978 ), as modified by Sharpe and Bartlett ( 1985 ) for an iodinated 
tracer. This assay used 0.1M PGBS buffer and synthetic testosterone ((Sigma) 
was used for standards. The antiserum 505 was used at a final dilution of 1 : 
2,800,000. The tracer was prepared by Chloramine T method. This involved 
reacting 125^ testosterone-carboxymethyl-oxime histamine and chloramine T. 
The reaction was terminated by addition of sodium metabisulphate and the 
labelled testosterone extracted with ethyl acetate. After volume reduction, the 
steroid fraction run on a thin-layer-chromatographic plate. The radioactive 
peak was removed and kept in ethanol at 4°C.
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The samples (50 pi) were extracted in hexane : ether and dried 
down under nitrogen. 200pl of 0.1M PGBS was added to the extract for 
reconstitution. To 100 pi of the reconstituted extract was added 100 pi of 
antiserum and then 100 |il of tracer. The tubes were then mixed and left on 
bench for 3h before adding 200 pi of the second antibody. The tubes were 
incubated overnight before centrifugation the following day. The supernatant 
was tipped off and the precipitate was counted. The lower limit of detection of 
the assay was 5 pg/ml and the mean intra- and inter- assay C. V. were 9.9% and 
12.7%, respectively, based on 5 assays.
3.4.7 FSH assay
The plasma concentrations of FSH were measured in duplicate by RIA 
using the method described by McNeilly, McNeilly, Walton and Cunningham 
(1976 ). This assay used 0.1% BSA/PBS as buffer and the reference standard 
was NIAMDD FSH-14 ( Bethesda, U. S.. A ). The antiserum NIAMDD-Anti- 
oFSH-1 ( AFP-C5288113 ) ( Bethesda, U. S. A .) was used at a final dilution of 
1 : 48,000. The tracer was prepared by the Lactoperoxidase method as 
described for PRL assay.
The assay procedure involved taking 150 p.1 of sample to which was 
added 150 pi of buffer and 50 pi of first antibody. Then, the mixture was 
incubated at for a day at 4°C. On the second day, 50 pi of tracer were added 
and the tubes were incubated overnight at 4°C. On the third day, 200 pi of 
second antibody were added and the tubes were again incubated at 4°C. On the 
fourth day, the tubes were spun and the supernatant was discarded while the 
precipitate was counted. The lower limit of detection of the assay was 4 ng/ml. 
All samples for FSH measurement were done in one assay.
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1 5  STATISTICAL ANALYSIS
Results were tested for significance by analysis of variance 
(ANOVA) using the CLR ANOVA computer program (Clear Lake Research, 
Houston, USA), followed by Newman Keul's ( NK ) test or simple effects 
where appropriate. Further details of analyses are given under the respective 
experiments where necessary.
CHAPTER 4
CYCLES IN B-END SECRETION: INFLUENCE OF SEASON. 
PHOTOPERIOD AND GONADAL STEROIDS
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M  INTRODUCTION
A clearly defined cycle in the peripheral plasma concentrations of 
B-END has recently been described in the Soay rams; the levels of B-END are 
1 0 -to-2 0  times higher in late summer and autumn than in winter and spring. 
This cycle in B-END secretion was also shown to be greatiy influenced by 
changes in photoperiod; the levels of B-END are high under short days and low 
under long days, showing a close correlation with the changes in the gonads and 
an inverse relationship with the levels of PRL (Ebling and Lincoln, 1987). The 
studies described in the first part of this chapter were undertaken: (i) to 
investigate in more detail the cycle in B-END secretion in relation to body 
weight, reproduction and changes in the secretion of other hormones; (ii) to 
compare the amount of Nac-B-END with that of total B-END in the peripheral 
blood in order to determine the relative contribution by the anterior and 
intermediate lobes, based on the observation that Nac-B-END is primarily 
secreted by the intermediate lobe (Antoni, 1986; Smith and Funder, 1988); and
(iii) to establish whether the cycle in B-END secretion seen in the Soay rams 
also applies to other breeds of sheep, for example the less seasonal Merino 
breed. The studies described in the second part of the chapter were carried out 
to complement the study of the cycle in B-END secretion; for this, samples 
taken from other studies investigating the effect of photoperiod and melatonin 
on reproduction were used (Lincoln and Ebling, 1985; Lincoln, Libre and 
Merriam, 1989a).
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4.2 EXPERIMENT 1- INFLUENCE OF SEASON IN SO AY RAMS
LIVING OUTDOORS
4.2.1 Aims
The aims of this experiment were to confirm whether there is a 
clearly defined cycle in B-END secretion related to season, and to determine the 
ratio of Nac-B-END to total 6 -END at three stages of the cycle. Also, to find 
out whether there is a cycle in ACTH and cortisol secretion paralleling the 
cycle in B-END secretion.and to relate the cycle in B-END secretion to other 
endocrine cycles, like those in PRL secretion and reproduction.
4.2.2 Materials and methods
A group of twelve adult Soay rams living outdoors in grass
paddocks was used in this experiment. Blood samples were collected weekly 
and body weight and testis diameter were recorded for each ram fortnightly 
for a period of one year. Plasma was assayed for the measurement of B-END, 
Nac-B-END (measured in February, May and August), ACTH, cortisol, PRL, 
FSH and testosterone as previously described (chapter 3, section 3.4).
4.2.3 Results
The seasonal changes in the plasma concentrations of B-END related 
to the seasonal changes in the plasma concentrations of ACTH, cortisol, PRL, 
and to changes in reproduction and body weight are illustrated in Fig. 4.1. 
There were highly significant (P < 0.001, ANOVA) changes with respect to 
time of the year in all the variables. The plasma concentrations of B-END 
increased some 1 0 -to-2 0 -fold from spring to summer, with the seasonal peak 
occurring in August. At the peak of the seasonal cycle, the ratio of B-END to 
Nac-B-END was found to be 22 : 1 (Table 4.2). The plasma concentrations of
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Fig. 4.1(a). Seasonal changes in the blood plasm a concentrations of B- 
endorphin, ACTH, corisol and prolactin in outdoor Soay rams. The values are 




Fig. 4.1(b). Seasonal changes in the blood plasma concentrations of FSH and 
testosterone, diameter of the testes and body weight in outdoor Soay rams. The 
values are means ±  SEM, n=12. The broken line indicates the time of summer 
solstice.
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Table 4.2. Plasma concentrations of B-endorphin and N-acetyl-B-endorphin in 
outdoor rams in February, May and August. Values are means ± SEM ( pg/m l) 




228.01 ±26.85 313.05 ±36.20
Undetectable Undetectable 





ACTH also increased markedly from spring to summer, reaching a seasonal 
peak in June and July some 1 to 2 months earlier than the peak in B-END 
secretion. The plasma concentrations of cortisol increased abruptly in spring at 
a time coincident with the seasonal increase in the plasma concentrations of 
ACTH, and reached a peak in May and June. The plasma concentrations of PRL 
also increased from spring to summer, to reach a peak in June some 1 to 2 
months earlier than the peak in B-END secretion (Fig. 4 .1 (a)).
The plasma concentrations of FSH increased from summer to 
autumn and there were associated increases in testis diameter and the plasma 
concentrations of testosterone. The animals' overall body weight increased 
from spring to summer, with the highest weights occurring in autumn 
(Fig. 4.1(b)).
4 3  EXPERIMENT 2-INFLUENCE OF SEASON IN SOAY AND
MERINO RAMS LIVING OUTDOORS
4.3.1 Aim
The aim of this experiment was to establish whether the cycle in 
B-END secretion observed in the Soay breed also occurs in the Merino, which 
is a less seasonal breed in its reproduction, and to compare the two breeds with 
crossbred animals produced by mating a Merino ram with Soay ewes . The 
seasonal changes in PRL secretion were also monitored to provide a second 
example of a hormone influenced by season.
4.3.2 Materials and methods
This experiment involved a group of seven adult Merino rams and
four adult Soay X Merino rams kept outdoors in grass paddocks. Blood 
samples were collected from each ram weekly for a period of one year, and
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plasma was assayed for the measurement of 6 -END and PRL as previously 
described (chapter 3, section 3.4). The results are compared with the data for 
purebred Soay rams described in experiment 1.
4.3.3 Results
The seasonal changes in the plasma concentrations of 6 -END and 
PRL in the Soay, Merino and crossbred rams are illustrated in Fig. 4.3. 
Compared with the Soay rams, the Merino rams showed a poorly defined cycle 
in the plasma concentrations of 6 -END (no significant changes in the plasma 
concentrations of 6 -END with respect to time of the year), and the crossbred 
rams showed a pattern intermediate between that characteristic of the parents. 
In contrast, there was a clearly defined seasonal cycle in the plasma 
concentrations of PRL in the Merino rams, not significantly different in timing 
or amplitude from that in the Soay or crossbred rams(Fig. 4.3 ).
4 4  EXPERIMENT 3-INFLUENCE OF PINEALECTOMY IN SOAY
RAMS LIVING OUTDOORS
4.4.1 Aim
The aim of the study was to establish whether the cycle in 6 -END 
secretion in outdoor rams is modified by removal of the pineal gland.
4.4.2 Materials and methods
A group of eight adult Soay rams living outdoors in grass paddocks 
was studied for a period of one year. Five of these rams were PINX and the 
other three of similar age received a sham operation to act as controls. The 
surgical operation of pinealectomy was carried out by Dr. G. A. Lincoln 






M O N T H S
Fig. 4.3. Seasonal changes in the blood plasma concentrations of B-endorphin 
and prolactin in outdoor Soay (#■), Soay X Merino ( X ) and Merino ( O ) rams. 
The values are means ± SEM, n=12 Soay, 4 Soay X Merino and 7 Merino rams. 
The Soay X  Merino rams were produced by mating a Merino ram with a group 
of Soay ewes.
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(1970). Blood samples were collected from each ram fortnightly for a period 
of one year and plasma was assayed for the measurement of 6 -END and PRL as 
previously described (chapter 3, section 3.4).
4.4.3 Results
The seasonal changes in the plasma concentrations of 6 -END and 
PRL are illustrated in Fig. 4.4. In the control rams, there was a clearly defined 
seasonal cycle in the plasma concentrations of 6 -END and PRL. In the PINX 
rams, the cycle in 6 -END secretion was disrupted as revealed by ANOVA 
followed by simple effects, whereas the cycle in PRL secretion was not 
significantly different from that in the control rams (Fig. 4.4(a) and (b)).
4.5 EXPERIMENT 4- INFLUENCE OF MELATONIN IMPLANT­
ATION IN SO AY RAMS LIVING OUTDOORS
4.5.1 Aim
Based on the knowledge that melatonin is the pineal hormone which 
relays the effect of photoperiod, the aim of this experiment was to establish 
whether administration of melatonin will interfere with the normal seasonal 
cycle in 6 -END secretion in rams living outdoors
4.5.2 Materials and methods
A group of sixteen yearling Soay rams living outdoors was used in 
this experiment. Eight of these rams were treated for 10 weeks, starting in May 
(beginning of long days), with Silastic implants containing melatonin. The 
implants were prepared, according to the method of Lincoln & Ebling (1985), 
from Silastic sheeting (500-1 Dow Coming, Midland, MI, U. S. A) sealed into 
an envelope with a total surface area of 32-42 cm^, containing 1-4 g melatonin
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Fig. 4.4(a). Seasonal changes in the blood plasma concentrations of 6 -endorphin 
in outdoor control and PINX rams. The values are means ±  SEM, n=3 control 














Fig. 4.4.(b). Seasonal changes in the blood plasma concentrations of prolactin in 
outdoor control and PINX rams. The values are means ±  SEM, n=3 control and 
5 PINX rams. The open bar indicates the period of pinealectomy.operation.
(Sigma Chemicals, Poole, Dorset, U. K), and were placed beneath the skin 
above the rib cage while the animals were locally anaesthetized with lignocaine. 
The implants maintained daytime melatonin concentrations of approximately 
250 pg/ml compared with 34 pg/ml in untreated rams and night concentrations 
of 500 pg/ml compared with 200 pg/ml in control rams (Lincoln and Ebling, 
1985). The other eight rams received empty implants to act as sham-operated 
controls. Blood samples were collected from each ram weekly for a period of 
12 weeks and plasma assayed for the measurement of B-END and PRL as 
previously described (chapter 3, section 3.4).
4.5.3 Results
Changes in the plasma concentrations of B-END and PRL are 
illustrated in Fig. 4.5. There were highly significant (P < 0.001, ANOVA) 
changes with respect to time in the plasma concentrations of both hormones in 
the two groups. In the control ram s, the seasonal peak in the plasma 
concentrations of B-END was in August, while the peak in PRL was 1-2 months 
earlier in June and July, as seen in the previous experiments. Implantation with 
melatonin caused an acceleration in the increase of B-END levels and a decrease 
in PRL levels. Within one week of implantation with melatonin the treated 
group was significantly (P < 0.005, ANOVA followed by Newman Keul's test) 
different from the control group for both hormones (Fig. 4.5).
4.6 EXPERIMENT 5- INFLUENCE OF PHOTOPERIOD IN SOAY
R AMS LIVING INDOORS
4.6.1 Aim
To further investigate the role of photoperiod, a series of 
experiments were conducted on Soay rams living indoors. The aim of the first
8 0 .
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Fig. 4.5. Changes in the blood plasma concentrations o f B-endorphin and 
prolactin in outdoor control ( O ) and melatonin-implanted ( • )  Soay rams. The 
values are means ±  SEM, n= 8  control and 8 melatonin-implanted rams. The 
implants were introduced in May (week 0) and were left in place for 10 weeks. 
The rectangular box indicates the period of melatonin implantation.
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experiment was to confirm the effect of exposing rams to an artificial lighting 
regimen of alternating 16-week periods of long days and short days on 6 -END 
and PRL secretion.
4.6.2 Materials and methods
A group of seven adult Soay rams housed indoors and exposed to an 
artificial lighting regimen of alternating 16-week periods of long days (16L : 
8D) and short days (8L : 16D) was used in this experiment. Blood samples were 
collected from each ram weekly for 39 weeks, and plasma was assayed for the 
measurement of 8 -END and PRL as previously described (chapter 3, section 
3.4).
4.6.3 Results
Changes in the plasma concentrations of 8 -END and PRL are 
illustrated in Fig. 4.6. There were highly significant (P < 0.001, ANOVA) 
changes with respect to time in the plasma concentrations of both hormones; the 
plasma levels of 8 -END were lowest during exposure to long days and highest 
during short days, reaching a peak 4-8 weeks after the start of short days. The 
reverse changes occurred in the plasma concentrations of PRL.
4 7  EXPERIMENT 6 - INFLUENCE OF MELATONIN IN SOAY
RAMS LIVING INDOORS
4.7.1 Aim
The aim of the second experiment on the indoor rams was to 
observe whether administration of melatonin will induce changes in the plasma 
concentrations of 8 -END and PRL as observed in the outdoor rams, and to
82 .
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Fig. 4.6. Changes in the blood plasma concentrations of 6 -endorphin and 
prolactin in indoor Soay rams exposed to alternating 16-week periods of long 
days (16h l ig h t : 8h darkness; 16L : 8D; LD) and short days (8L : 16D; SD) for 
39 weeks. The values are means ± SEM, n=7 rams.
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establish w hether the long term treatm ent with m elatonin blocks the 
photoperiodically induced cycles in 6 -END and PRL secretion.
4.7.2 Materials and methods
A group of eight adult Soay rams housed indoors was pre­
conditioned to an artificial lighting regimen of alternating 10-30-week periods 
of long days (16L : 8D) and short days (8L : 16D). At week 14 during long 
days, four of the rams received melatonin implants and the other four received 
empty implants to act as sham-operated controls as described in experiment 4. 
The implants remained in place throughout the period of study during which 
the rams were exposed to alternating 10-16 week periods of long days and 
short days. Blood samples were collected from each ram weekly for a period of 
86  weeks and plasma was assayed for the measurement of 8 -END and PRL as 
previously described (chapter 3, section 3.4). 8 -END was measured for 86 
weeks while PRL was measured for 67 weeks.
4.7.3 Results
Changes in the plasma concentrations of 8 -END and PRL are 
illustrated in Fig. 4.7. At the start of the experiment under long days, the 
plasma concentrations of 8 -END were low and the concentrations of PRL were 
high in both groups. Implantation with melatonin at week 14 resulted in an 
increase in the plasma concentrations of 8 -END and a decrease in the plasma 
concentrations of PRL. At a later stage, the changes in the photoperiod between 
long days and short days resulted in cyclical changes in the concentrations of 
both hormones in the control rams but the pattern was modified in the 
melatonin-im planted rams. The plasm a concentrations of 8 -END in the 
m elatonin-im planted rams remained relatively higher while the plasma 
concentrations of PRL remained relatively lower throughout the study and 
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Fig. 4.7(a). Changes in the blood plasma concentrations of 6 -endorphin in 
indoor control (upper panel) and melatonin-implanted (lower panel) Soay rams 
exposed to alternating 10-30 week periods of long days ( 16h lig h t: 8h darkness; 
16L : 8 D; LD) and short days ( 8L : 16D; SD) for 8 6  weeks. The values are 
means ±  SEM, n=4 control and 4 melatonin-implanted rams. The implants were 
introduced at week 14 during long days and left in place throughout the 
remainder of the study. The rectangular box indicates the period of implantation 
















Fig. 4.7(b). Changes in the blood plasma concentrations of prolactin in indoor 
control (upper panel) and melatonin-implanted (lower panel) Soay rams exposed 
to alternating 10-30 week periods of long days (16h light : 8 h darkness; 16L : 
8D; LD) and short days (8L :16D; SD) for 67 weeks. The values are means ± 
SEM, n= 4  control and 4 m elatonin-im planted ram s. The implants were 
introduced at week 14 during long days and left in place throughout the 
rem ainder o f the study. The rectangular box indicates the period of implantation 
with empty implants (open) and with melatonin implants (dotted).
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4.8 EXPERIMENT 7- INFLUENCE OF GONADAL STEROIDS IN
SOAY RAMS LIVING INDOORS
4.8.1 Aim
Seasonal changes in the reproductive axis occur in parallel with the 
changes in 13-END secretion and it is possible that gonadal steroids induce or 
modify the pattern of 13-END secretion. The aim of the third experiment on 
indoor rams was to record the photoperiod-induced cycle in 13-END secretion 
in groups of rams in which the gonadal steroids had been removed by castration 
or held constant by implantation with testosterone.
4.8.2 Materials and methods
Three groups of six yearling Soay rams were housed indoors under 
an artificial lighting regimen of alternating 16-week periods of long days (16L 
: 8D) and short days (8L : 16D). Groupl was not surgically manipulated and 
acted as controls (intacts group). Group 2 was castrated by the removal of the 
testes and epididymides at the beginning of the experiment at 12  weeks into 
long days (castrates group). Group 3 was implanted with testosterone and 
castrated at the beginning of the experiment (castrates + T group). The rams in 
group 3 were given a Silastic implant containing testosterone placed beneath the 
skin overlying the rib cage using a local anaesthetic. The implants were made 
from Silastic sheeting (500-1 Dow Coming, Midland, MI, U. S. A) sealed into 
an envelope with a surface area of approximately 40 cm ^, containing 2g 
testosterone (Sigma Chemicals, Poole, Dorset, U. K.). The implants maintained 
circulating concentrations of testosterone of 6-10 ng/ml, declining slowly to 3- 
6  ng/ml from 50-96 weeks. Blood samples were collected weekly from each 
ram in all the three groups for a period of 96 weeks starting 8 weeks into long 
days; and plasma was assayed for the measurement of 13-END and PRL as 
previously described (chapter 3, section 3.4).
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Fig. 4.8(a). Long-term changes in the blood plasma concentrations of 
B-endorphin in indoor Soay rams exposed to alternating 16-week periods of 
long days (16h light : 8h darkness; 16L : 8D; LD) and short days (8L : 16D; 
SD) for 96 weeks. The values are means ± SEM, n= 6  rams per group, (a) One 
group of six rams was not surgically manipulated (intacts); (b) another group 
of six rams was castrated at week 12 during long days (castrates); (c) the third 
group was castrated and then implanted with testosterone at week 12  during 
long days (castrates + T). C indicates the time of castration and C + T indicates 
















1 0 0 0 - 
500- 
0 -














W E E K S
89.
Fig. 4.8(b). Long-term changes in the blood plasma concentrations of prolactin 
in indoor Soay rams exposed to alternating 16-week periods of long days (16h 
lig h t: 8 h darkness; 16L : 8D; LD) and short days (8L : 16D; SD) for 96 weeks. 
The values are means ±  SEM, n-6  per group, (a) One group of six rams was not 
surgically manipulated (intacts); (b) another group of six rams was castrated at 
week 12  during long days (castrates); (c) the third group was castrated and then 
implanted with testosterone at week 12 during long days (castrates + T). C 
indicates the time of castration and C + T indicates the time of castration plus 
testosterone implantation.
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4.8.3 Results
Changes in the plasma concentrations of 6 -END and PRL are 
illustrated in Fig. 4.8. There were highly significant (P < 0.001, ANOVA) 
changes with respect to time in the plasma concentrations of 6 -END and PRL in 
intact, castrate and castrate + T rams. The plasma levels of 6 -END were low 
during exposure to long days and high during exposure to short days; the 
reverse changes occurred in the plasma levels of PRL (Fig. 4.8(a) and (b)), 
similar to the situation observed in experiment 5. When the data was divided 
into 16-week periods of long and short days and analysed by a 3 X 2 way 
ANOVA for each of the three 32-week cycles, there were no significant 
difference between the three groups (intacts, castrates and castrates + T; Fig. 
4.8(a) and (b)).
L 9 DISCUSSION
The studies described in this chapter have primarily examined the 
influence of season and photoperiod on the secretion of 6 -END into the 
peripheral blood of Soay rams. The results obtained on rams living outdoors 
illustrate that there is a clearly defined seasonal cycle in 6 -END secretion with 
the highest circulating concentrations occurring in autumn and the lowest 
concentrations occurring in winter. This is a similar pattern to that described 
previously for Soay rams (Ebling and Lincoln, 1987), and confirms that the 
cycle in 6 -END secretion is closely associated with the cycle in body weight, 
which is consistent with a role of 6 -END in the regulation of carbohydrate 
metabolism and lipogenesis. The results also show that there is a seasonal cycle 
in ACTH and cortisol secretion in the Soay ram, paralleling the seasonal cycle 
in 6 -END secretion (experiment 1), which indicates a parallel secretion of 
ACTH and 6 -END from corticotrophs in the anterior lobe of the pituitary
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gland. This close relationship between ACTH and B-END secretion further 
confirm s the role of 8 -END in metabolism and fattening. In addition, a 
parallelism between the seasonal cycle in cortisol secretion, body weight and 
fat deposition has been observed in another seasonal species, the reindeer 
(Nilssen, Bye, Sundsford and Blix, 1985). If there is a close relationship 
between the seasonal cycle in B-END, cortisol and body weight in the Soay ram, 
it is not unreasonable to further conclude that 8 -END is involved in fat 
deposition in the ram.
The study comparing the seasonal cycle in B-END secretion between 
the Soay and Merino breeds illustrates that Merino rams do not show a seasonal 
cycle in B-END secretion, which reflects a lack of seasonality (experiment 2). 
This lack of seasonality is well known for the reproductive system and is likely 
to apply to other aspects of the animals' physiology. However, the observation 
that there was a seasonal cycle in PRL secretion indicates that the Merino breed 
is not entirely non-seasonal, which suggests that the genetic mechanisms 
responsible for the differences between the Soay and Merino breeds are 
specific to the reproductive axis and the corticotrophs/melanotrophs, but they 
do not seem to affect the lactotrophs. The crossbred rams, produced by mating 
Soay ewes with a Merino ram, had a seasonal cycle in B-END secretion 
interm ediate in am plitude between that characteristic of the parents, 
demonstrating the genetic basis for the differences between the Soay and 
Merino breeds (experiment 2).
The current results show clear evidence for the influence of 
photoperiod on B-END secretion as previously described for the reproductive 
axis (Lincoln and Ebling, 1985). Also they show, for the first time, that 
treatment with melatonin affects the secretion of B-END, which is consistent 
with the role of melatonin in relaying the effects of photoperiod on this 
endocrine system. Exposure to short days stimulates, and exposure to long days
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inhibits, B-END secretion, opposite to the effect on PRL secretion. 
Implantation with melatonin, initiated under long days, causes an increase in B- 
END secretion both in outdoor (experiment 4) and in indoor (experiment 6 ) 
rams. This treatment, which results in continuous melatonin exposure, blocks 
the effect of long days and has the effect of mimicking the effect of short days 
in the long term. Melatonin implantation interferes with the photoperiodically- 
induced cycles in B-END secretion, presumably because it obscures the 
endocrine signal produced by endogenous melatonin.
The timing of the seasonal cycle in outdoor rams relative to a 
change from long to short days is different from the timing of the long-term 
cycle seen in indoor rams. This is explained by the differences in the duration 
of exposure to long and short days in these two situations. In the outside 
environment, the rams are exposed to a natural light cycle of 52 weeks (26- 
week periods of alternating long and short days); in an indoor environment, the 
rams are exposed to an artificial light cycle of 32 weeks (16-week periods of 
alternating long and short days). As the animals remain exposed to the same 
photoperiod for a long time, they become refractory to the prevailing 
photoperiod. For example, prolonged exposure to long days causes a decrease 
in B-END secretion but after 20 weeks the levels increase as the animals become 
refractory to the inhibitory long days (experiment 6 ). This also accounts for 
the rise in B-END secretion seen in outdoor rams from May through the long 
days of June and July; a similar explanation can be invoked for the decline in 
B-END secretion which occurs in September and November during short days 
(experiment 1).
The results also illustrate that, in the natural environment, 
photoperiod may not be the only environmental variable influencing the 
seasonal cycle in B-END secretion. In the current study, pinealectomy 
disrupted the seasonal cycle in B-END secretion but it did not render the
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animals totally unresponsive to season (high plasma levels of 8 -END in summer 
and low plasma levels in winter; experiment 3). The effect of pinealectomy has 
been studied in more detail in Soay rams for the control of reproduction and 
PRL secretion (Lincoln et al., 1989a). In these studies, the cycle in reproduction 
continued, although with a different timing, that in PRL secretion persisted 
after pinealectomy, indicating that these cycles were being driven by other non- 
photoperiodic environmental cues. For example, a change in temperature plays 
a major role in regulating the seasonal cycle in PRL secretion (Lincoln, 1989a), 
while a change to good quality nutrition reactivates testicular activity (Lincoln 
et al., 1989a). Therefore, influence of changes in temperature and nutrition 
may account for the persistence of the seasonal changes in 8 -END secretion 
after pinealectomy.
In the Soay ram, the seasonal changes in the reproductive axis occur 
in parallel with the seasonal changes in 8 -END secretion (Ebling and Lincoln,
1987). However, there seems to be no consistent relationship between 
reproduction and 8 -END secretion across seasonal species. For example, in the 
hamster, the reproductive axis is most active under long days when 8 -END 
levels are low, and it is least active under short days when 8 -END levels are 
high. In the current study, removal of testes or replacement with testosterone 
did not interfere with the photoperiod-driven cycle in 8 -END secretion in 
indoor rams, which indicates that the control of 8 -END secretion from the 
pituitary gland is independent of the reproductive axis (experiment 7).
4.10 SUMMARY
This first series of experiments has established the following:
1. There is a cycle in 8 -END secretion in the Soay ram related to 
season and photoperiod.
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2. There is also a seasonal cycle in the plasma concentrations of 
ACTH and cortisol secretion in the Soay ram.
3. There are genetic differences between breeds with regard to the 
seasonal cycle in 6 -END secretion
4. Pinealectomy disrupts the seasonal cycle in 6 -END secretion and 
treatment with melatonin modifies the photoperiodically-induced cycle in 6 - 
END secretion, which is consistent with the role of melatonin from the pineal 
gland in mediating the effect of photoperiod on 6 -END secretion.
5. Castration and testosterone replacem ent therapy does not 
influence the photoperiodically-induced cycle in 6 -END secretion, indicating 
that the cycle in 6 -END secretion is not dependent on the changes in the 
reproductive axis.
6 . There is usually an inverse relationship between the cycle in 6 - 




CONTROL OF THE SEASONAL CYCLE IN fi-END 
SECRETION: ROLE OF AVP. CRF AND GLUCO­
CORTICOIDS
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5 1  INTRODUCTION
The 6 -END in the peripheral blood is secreted primarily from 
the pituitary gland since this tissue contains much larger amounts of 6 -END 
compared with other tissues in the body (Ebling and Lincoln, 1987; Ebling 
et al., 1987; Smith and Funder, 1988). Both the corticotrophs and 
melanotrophs in the pituitary gland secrete 6 -END (Antoni, 1986; Smith 
and Funder, 1988). The neural control of the secretory activity of the 
corticotrophs involves stimulation by hypothalamic AVP and CRF, and 
inhibition by adrenal glucocorticoids. In sheep, AVP and CRF have been 
measured in the pituitary portal blood system (Engler et al., 1989b) and 
both these peptides have been shown to stimulate the secretion of 6 -END, 
ACTH and cortisol in short-term studies (Donald et al., 1983; Redekopp et 
al., 1985b; Pradier et al., 1986; Familari et al., 1989).Also glucocorticoids 
have been shown to inhibit the secretion of both 6 -END and ACTH (Engler 
et al., 1989a). However, it is not clear whether these mechanisms, which 
involve a parallel change in adrenal axis, can account for the regulation of 
the seasonal cycle in 6 -END secretion on a long-term basis.
The aims of the studies described in this chapter were to 
investigate the role of AVP, CRF and glucocorticoids in the control of the 
seasonal cycle in 6 -END secretion in the ram and to examine more closely 
the relationship between 6 -END, ACTH and cortisol secretion.
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5.2 EXPERIMENT 8- DOSE RESPONSE TO AVP IN SUMMER
AND WINTER
5.2.1 Aim
The aim of this experiment was to assess whether AVP would elicit a dose- 
dependent increase in the plasma concentrations of B-END in the Soay ram 
and to compare the response at the peak and nadir of the seasonal cycle in 13- 
END secretion.
5.2.2 Materials and methods
The twelve outdoor rams used to study the seasonal cycle in B-END 
secretion (experiment 1) were employed in this experiment. The rams were 
treated i.v with either saline or three doses of AVP (0.07, 0.33 and 1.67 pig/kg ) 
in summer (July) and winter (December) of the first year of the study. The 
treatment design and bleeding protocol was as follows: each ram received 
saline or AVP at one of the doses on two consecutive days in a randomized 
design (six rams / treatment group). The low dose of AVP was selected on the 
basis of previous studies in sheep (Redekopp et al., 1985). Blood samples were 
collected 2 0  min before and for 2 h after the i.v. injection, starting at 13.40h 
(sampling times -20, -10, 0, 10, 20, 30, 40, 50, 60, 75, 90, 105 and 120 min
relative to the injection). The treatments were carried out at the same time of
the day in both summer and winter; this provided consistency although there is 
no clear evidence for a diurnal rhythm in the hypothalamic-pituitary-adrenal 
axis in the Soay ram (Lincoln, Almeida, Klandorf and Cunningham, 1982; 
Ebling and Lincoln, 1987). Plasma was assayed for the measurement of B-END 
as previously described (chapter 3, section 3.4).
To assess the response to AVP the increm ental changes were 
calculated for each animal using the mean pretreatment values (three samples
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collected 0-20 min before the AVP injection) and subtracting this from the 
post-treatm ent values (ten samples collected from 1 0 -1 2 0  min after the 
injection). A single mean value for the period 10-60 min was then calculated 
for each animal and the overall mean for the treatment group was determined 
to represent the mean incremental response. The statistical significance of the 
response was assessed by ANOVA (chapter 3, section 3.5).
5.2.3 Results
The incremental changes in the plasma concentrations of 13-END 
following treatment with saline, low, medium and high doses of AVP in 
sum m er (July, high endogenous 13-END concentrations) and w inter 
(December, low endogenous 13-END concentration) are summarized in Table 
5.1. In both seasons, AVP induced a dose-dependent increase in the plasma 
concentrations of 13-END. The slope of the response was greater in winter than 
in summer; in winter even the lowest dose of AVP (0.07 p.g/kg) induced a 
significant increase in the plasma levels of 13-END.
There was a minor behavioural response following the injection of 
the medium and high doses of AVP. This involved the rams standing up and 
becoming slightly restless for 1 to 5 min after the injection. The behavioural 
response was more conspicuous in July than in December.
5 3  EXPERIMENT 9- EFFECT OF AVP AND CRF ON B-END AND
ACTH SECRETION AT THE FOUR SEASONS OF THE YEAR
5.3.1 Aim
The aim of this experiment was to investigate whether AVP and 
CRF given alone or in combination will induce an increase in B-END and
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Table 5.1. Changes in the plasma concentrations of B-END in outdoor rams 
after receiving saline or three doses of arginine vasopressin in summer and 
winter. Values are means ± SEM ( pg /m l), n= 6  rams/treatment group.




AVP (0.07 p.g/kg) 
AVP (0.33 pg/kg) 
AVP (1 .67 pg/kg)
186.20 ± 24.80
204.95 ± 47.70 
783.50 ± 250.20** 
2736.35 ±  758.00***
0.55 ±  9.60 
38.40 ± 20.45*
269.20 ±  140.65** 
3816.60 ± 1471.45***
*P < 0.05, ** P < 0.01, *** P < 0.001 compared with the corresponding saline
group, ANOVA followed by Newman Keul's test.
ACTH secretion and to measure the changes in response at different times of 
the year related to the seasonal cycle in B-END secretion.
5.3.2 Materials and methods
The twelve outdoor rams used to study the seasonal cycle in B-END 
and ACTH secretion (experiment 1) were employed in this experiment. The 
rams were treated with AVP and/or CRF in spring (April), summer (July), 
autumn (September) and winter (December) of the first year of the study. AVP 
was given i.v. at a dose of 0.33 pg/kg made up to 1 ml with physiological saline 
(dose selected from experiment 8 ) and CRF was given as an equimolar dose of 
1.67 pg/kg. The treatment design and bleeding protocol was as in experiment 8 . 
Plasma was assayed for the measurement of B-END and ACTH as previously 
described (chapter 3, section 3.4). The incremental increases were calculated 
for the post-treatment period 10-60 min as described in experiment 8 , and the 
significance of the change was assessed by ANOVA (chapter 3, section 3.5).
5.3.3 Results
The effects of AVP and CRF on the plasma concentrations of B- 
END and ACTH in summer are illustrated in Fig. 5.2 and the incremental 
increases in hormone concentrations at the four seasons are summarized in Fig. 
5.3. The i.v. injections of AVP and CRF given separately caused a significant 
(P < 0.01, ANOVA) increase in the plasma concentrations of B-END; the levels 
were maximum 10  min after the injections and declined to pretreatment values 
within 60 min. The treatment with AVP plus CRF caused a significantly 
greater increase in the plasma concentrations of B-END than when the drugs 
were given separately. There was also an increase in the plasma concentrations 
of ACTH after the i.v. injection of AVP alone or in combination with CRF but 
there was no significant response after the injection of CRF alone (Fig. 5.2). 
The B-END and ACTH response to AVP and AVP plus CRF changed
102 .






Fig. 5.2. Plasma concentrations of B-endorphin and ACTH in outdoor Soay rams 
receiving a single bolus i.v. injection of either saline (O ), 1.67 jig corticotropin- 
releasing factor (CRF)/kg ( # ) ,  0.33 pig arginine vasopressin (AVP)/kg ( X ), or 
a combination of 1.67 jig CRF/kg and 0.33 jig AVP/kg ( A )  in summer. Values 
are means ±  SEM, n= 6  rams per treatment group. The solid arrow indicates the 
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Fig. 5.3. Summary of the incremental changes in the plasma concentrations of 
B-endorphin and ACTH in outdoor Soay rams after receiving a single bolus 
injection of either saline (C), 1.67 jig corticotrophin-releasing factor (CRF)/kg,
0.33 jig AVP/kg or a combination of 1.67 jig CRF/kg and 0.33 jig AVP/kg in 
spring, summer, autumn and winter. Values for each histogram are means ± 
SEM, n= 6  rams per treatment group. Asterisks indicate significant effects of the 
treatments: * P < 0.05 compared with C; ** P < 0.01, *** P  < 0.005 compared 
with CRF or AVP (Newman Keul's test following ANOVA).
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significantly (P < 0.01, ANOVA) with season; the greatest response occurred 
in summer for B-END and in autumn for ACTH. There was no significant 
seasonal change in the response to CRF given alone. At all seasons the 
synergistic effect of AVP plus CRF was clearly evident (Fig. 5.3).
The m inor behavioural response of restlessness described in 
experiment 8 was observed following the injection of AVP and AVP plus CRF, 
but not following CRF alone. This response was more conspicuous in summer 
and autumn than in winter and spring.
5A EXPERIMENT 10- EFFECT OF DEXAMETHASONE ON
B-END AND ACTH SECRETION AT THE FOUR
SEASONS OF THE YEAR
5.4.1 Aim
In this experiment, the synthetic glucocorticoid, dexamethasone, 
was administered at different times of the year to investigate the role of 
glucocorticoids in the inhibition of B-END and ACTH secretion.
5.4.2 Materials and methods
The twelve outdoor rams used to study the seasonal cycle in B-END 
and ACTH secretion (experiment 1) were employed in this experiment. Six of 
these rams were treated with dexamethasone in spring (April), summer (July), 
autumn (September) and winter (December) two weeks after each of the studies 
described in experiment 9. The other six rams received saline and acted as
controls. The treatm ent design and bleeding protocol was as follows:
dexamethasone was given i.v. at a dose of 5.67 |ig/kg every 10 min for 2h (total 
dose 68.04 |ig/kg). The dose of dexamethasone was selected on the basis of the
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infusion rate of 1 mg/h used in man (Samra, Dechaud, Estour, Chalendar, 
Fevre-Montange, Pugeat & Tourniaire, 1985). Blood samples were collected 
at 10  min intervals for 2 h before and 6 h after the beginning of the 
dexamethasone treatments. Plasma was assayed for the measurement of B-END 
and ACTH as previously described (chapter 3, section 3.4).
The incremental changes in the plasma concentrations of B-END 
and ACTH were calculated for each animal using the mean pretreatment values 
(th irteen sam ples collected 0 -2 h before the in jection  of saline or 
dexamethasone) and subtracting this from the post-treatment values (thirty six 
samples collected 0-6h after the injection). A single mean value for the three 
periods, 0-2, 2-4 and 4-6h, was calculated for each animal and the overall mean 
for each 2h-period for the two treatments was determined. The statistical 
significance of the differences between the treatment groups was assessed by 
ANOVA (chapter3, section 3.5). In this experiment, the correlation between 
the short-term fluctuations in the plasma concentrations of B-END and ACTH 
was also assessed using data for the 8h sampling period for the control rams in 
spring and summer during the seasonal period of increased secretion. For this, 
the peaks in plasm a concentrations of ACTH were firstly defined as two 
consecutive high values, at least one of which exceeded the mean of the 
previous two baseline values by > 2 times the intra-assay C. V. The mean 
plasma concentrations of ACTH relative to all the defined peaks was then 
calculated for each animal and the corresponding B-END values were also 
determined. A significant increase in the plasma concentrations of B-END at a 
time coincident with the ACTH peak (ANOVA with Newman Keul's test) was 
used as evidence for a correlation between the fluctuations in the concentrations 
of the two hormones.
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5.4.3 Results
The plasma B-END and ACTE1 profiles for the 8h blood sampling 
period for representative rams treated with saline or dexamethasone in summer 
are illustrated in Fig. 5.4, and the overall results are summarized in Fig. 5.5. In 
the saline-treated rams the plasma concentrations of B-END and ACTH 
fluctuated in a pulsatile manner but the mean levels for the group remained 
relatively constant throughout the 8 h sampling period. The treatment with 
dexamethasone resulted in a slow decline in the concentrations of B-END and 
ACTH, with the mean levels maximally suppressed at the end of the study, 6 h 
after the initiation of drug treatment (Fig. 5.4). The suppressive effect of 
dexamethasone on the plasma concentrations of B-END and ACTH changed 
significantly (P < 0.001, ANOVA; analysed for the last 2h of the study) with 
season, with the maximum responses for both hormones occurring in summer 
at the time of increased endogenous secretion (Fig. 5.5).
The temporal relationship in the short-term fluctuations in the 
plasma concentrations of B-END and ACTH was analysed in the individual 
control rams in spring and summer, and the results for one ram in summer are 
illustrated in Fig. 5.6(a). In two of the six rams, in both spring and summer, the 
peaks in the plasma concentrations of ACTH were correlated with a significant 
(P < 0.05, ANOVA) simultaneous increase in the plasma concentrations of B- 
END. This was also evident for the combined data for all animals (Fig. 5.6(b)). 
In no animal were all the ACTH peaks correlated with an increase in B-END.
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S U M M E R
M IN U T E S
Fig. 5.4. Plasm a (a) B-endorphin and (b) ACTH profiles in a representative Soay 
ram treated with either saline ( O  ) or dexamethasone ( #  ) in summer. The open 
box indicates the period of dexamethasone administration given as i.v. injections 
of 5.67 |ig/kg every 10 min for 2h (total dose of 68.0 fig/kg).
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Fig. 5.5. Summary of the incremental changes in the plasma concentrations of 
B-endorphin and ACTH in outdoor Soay rams after receiving an i.v. injection of 
saline (C) or 68.04 }ig dexamethasone (DEX)/kg. Values are means ±  SEM, n= 6  
rams per treatm ent group, calculated as the difference in hormone concentration 
between a 2h-period before treatment and the period between 4 and 6h after the 
start of administration of DEX. The asterisks indicate significant effects of the 
treatments: * P < 0.05, ** P < 0.005 compared with C (Newman Keul's test 
following ANOVA).
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S A M P LE  NO.
Fig. 5.6. (a) Temporal relationship between the peaks in plasma concentrations 
of B-endorphin (O )  and ACTH (%  ) in a representative Soay ram from the 
control group in summer. Each arrow depicts a significant ACTH peak as 
defined in the text. The values are based on blood samples collected at 10 min 
intervals for 8 h. (b) Summary of the mean plasma concentration of B-endorphin 
( O ) and ACTH ( #  ) related to the timing of all significant ACTH peaks for the 
data of all six control rams in summer.
1 1 0 .
5.5 EXPERIMENT 11 - EFFECT OF RU 486 ON 6 -END AND
CORTISOL SECRETION IN SUMMER AND WINTER
5.5.1 Aim
Having shown that dexamethasone significantly inhibited 6 -END 
and ACTH secretion in experiment 10, the aim of this experiment was to 
establish whether the blockade of endogenous glucocorticoids using the
synthetic glucocorticoid antagonist, RU 486, will cause an increase in 6 -END
\
and cortisol secretion, and to measure the response in summer and winter.
5.5.2 Materials and methods
Ten of the twelve outdoor rams used to study the seasonal cycle in 
6 -END and ACTH secretion (experiment 1) were employed in this experiment. 
Five of these rams were treated i.m. with RU 486 on six consecutive days in 
summer (July) and winter (December) of the second year of the study. The 
other five rams received saline to act as controls. The treatment design and 
bleeding protocol was as follows: On day 1, RU 486 was given at a dose of 1 
mg/kg and on day 2  it was given at a dose of 10 mg/kg in 8 ml total solution. 
The 8 ml total solution was injected at four different sites, i.e. 2 ml/site. On 
days 3-6, RU 486 was given at a dose of 2 mg/kg. The low and high doses of 
RU 486 were selected on the basis of previous studies in the monkey (Healy, 
Chrousos, Schulte, Gold & Hodgen,1985). Blood samples were collected at 10 
min intervals for 2 h before and 6 h after the beginning of the treatment on days
1, 2 and 6 . A single blood sample was collected to monitor the progress of the
treatment on days 3-5. Plasma was assayed for the measurement of 6 -END and 
cortisol (indirect measure for ACTH) as previously described (chapter 3, 
section 3.4).
i n .
The mean plasma concentrations of 6 -END and cortisol were 
calculated for each day based on the the 6h post-treament values (thirty six 
samples collected after the injection on days 1 , 2  and 6 ), and the significance of 
the effect of RU 486 was assessed by ANOVA (chapter 3, section 3.5).
5.5.3 Results
The effect of RU 486 on the mean plasma concentrations of 6 -END 
and cortisol on days 1 , 2  and 6 when serial blood samples were taken in summer 
amd winter is summarized in Fig. 5.7. In summer, the i.m. injection of RU 486 
at all doses used did not affect the mean plasma concentrations of 6 -END and 
cortisol. Although there was a tendency for the plasma levels of 6 -END in the 
treated group to increase above the levels in the control group on day 6 , this 
increase was not statistically significant. The single daily samples collected on 
days 3-5 also failed to show a significant effect of the treatment (results not 
shown). In winter, the i.m. injection of RU 486 did not affect the mean plasma 
concentrations of 6 -END and cortisol on day 1. However, the treatment 
significantly (P < 0.05 for 6 -END; P < 0.001 for cortisol, ANOVA) increased 
the plasma levels of both hormones on days 2 and 6 . There was no difference in 
hormone response between the acute treatment (day 2 ) and the chronic 
treatment (day 6 ).
5A EXPERIMENT 12- STUDY OF THE SITE OF GLUCO­
CORTICOIDS ACTION
5.6.1 Aim
The aim of this experiment was to assess whether glucocorticoids 
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5.6.2 Materials and methods
A group of five indoor rams was used in this experiment. The rams 
were treated with AVP with or without pretreatment with dexamethasone 
while maintained under short days (8  weeks after the change from long days to 
short days, equivalent to autumn in the outdoor animals). The treatment design 
and bleeding protocol was as follows: on day 1 the animals received no 
pretreatment with dexamethasone and were blood sampled at 10  min intervals 
for lh  before and lh  after the i.v. injection of AVP (1.07 [ig/kg). On day 2 the 
animals were pretreated with dexamethasone 5h (0.13 (ig/kg) and lh  (0.03 
p.g/kg) before receiving the i.v. injection of AVP and blood samples were taken 
as on day 1. The pretreatment dose of dexamethasone was selected based on the 
ability of dexamethasone to block ACTH secretion from the pituitary gland in 
the rat (Buckingham, 1987). Plasma was assayed for the measurement of 13- 
END as previously described (chapter 3, section 3.4).
For the analysis, the mean values for each lh-period following 
treatment with saline, AVP, dexamethasone and AVP plus dexamethasone, 
were calculated based on 10-min samples collected for a period of Ih before 
and lh  after the AVP injections, and the statistical significance of the treatments 
was assessed by ANOVA (chapter 3, section 3.5).
5.6.3 Results
The effect of AVP w ith or w ithout p retreatm ent w ith 
dexamethasone on the plasma concentrations of 13-END is summarized in Fig. 
5.8. In the absence of pretreatment with dexam ethasone, AVP caused a 
significant (P < 0.001, ANOVA) increase in the plasma concentrations of 13- 
END. However, pretreatment with dexamethasone suppressed the plasma 
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The m inor behavioural response of restlessness described in 
experiment 8 was observed following the injection of AVP, both with and 
without pretreatment with dexamethasone.
5/7 EXPERIMENT 13- EFFECT OF B-END AND ACTH ON
CORTISOL SECRETION AT THE FOUR SEASONS OF
THE YEAR
5.7.1 Aim
The aim of this experiment was to assess whether both B-END and ACTH can 
stimulate the secretion of cortisol and to compare the responses at different 
times of the year.
5.7.2 Materials and methods
The twelve outdoor rams used to study the seasonal cycle in B-END 
and ACTH secretion (experiment 1) were again employed in this experiment. 
The rams were treated i.v. with saline, B-END or ACTH in spring (April), 
summer (July), autumn (September) and winter (December) of the second year 
of the study. The treatment design was as follows: The animals were first 
pretreated i.v. with dexamethasone 5h (0.13 |ig/kg) and lh  (0.03 fig/kg) to 
block the secretion of endogenous B-END and ACTH, and then received i.v 
injections of B-END or ACTH . B-END and ACTH were given'at a dose of 0.33 
(ig/kg; this dose was selected to produce circulating concentrations of B-END 
similar to the values occurring at the peak of the seasonal cycle in Soay rams 
(Ebling & Lincoln, 1987). The bleeding protocol was as in experiment 8 . 
Plasma was assayed for the measurement of cortisol as previously described 
(chapter 3, section 3.4 ).
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Mean incremental responses were calculated as before (experiment 
8 ) and the statistical significance of the treatments was assessed for the period 
10-60 min post-treatment by ANOVA (chapter 3, section 3.5).
5.7.3 Results
The incremental changes in the plasma concentrations of cortisol 
following treatment with saline, 8 -END or ACTH in spring, summer, autumn 
and winter are illustrated in Fig. 5.9. W hile ACTH significantly (P < 0.001, 
ANOVA) increased the plasma concentrations of cortisol at all the seasons, 8 - 
END had no effect. The cortisol response to ACTH varied significantly (P <
0.01, ANOVA) with season; this was greatest in spring at the peak of the 
seasonal cycle in cortisol secretion (Fig. 5.9).
I
5j£ DISCUSSION
The peptides AVP and CRF are located in the neurosecretory cells of 
the hypothalamus and are thought to be the principal regulators of 8 -END and 
ACTH secretion from the pituitary gland (Rivier & Vale, 1983a; Antoni, 1986;
Smith & Funder, 1988). The current studies show that both AVP and CRF
stimulate the release of 8 -END and ACTH in the Soay ram, and the pituitary 
response is increased in summer and autumn at the time of increased 
endogenous secretion. This is consistent with the view that seasonal changes in 
AVP and/or CRF may dictate the seasonal cycle in 8 -END and ACTH secretion. 
AVP was relatively more potent than CRF, on a molar basis, in stimulating the 
secretion of 8 -END and ACTH, which is consistent with previous studies in 
other breeds of sheep (Pradier et al., 1986; Familari et al., 1989; experiments 8 
and 9). Measurements of the concentrations of AVP and CRF in the pituitary 
portal blood system of sheep have revealed relatively higher concentrations of 
AVP than CRF, which could be taken to indicate that AVP is the more
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R g. 5.9. Changes in the plasma concentrations of cortisol in outdoor Soay rams 
following a single bolus injection of either saline (O ), 0 .3 3  jig B-endorphin/kg 
( • )  or 0.33 jig ACTH/kg (X ) in spring, summer, autumn and winter. Values are 
means ±  SEM , n= 6  rams per treatment group. The injection was given at time 0.
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important physiological regulator of this endocrine system (Engler et al., 
1989b). However, the observation of a synergistic response to AVP and CRF in 
the Soay ram at all seasons of the year is consistent with a role for both 
hypothalamic peptides in the control of 6 -END and ACTH secretion.
The studies also illustrate the involvem ent of the adrenal 
glucocorticoids in the negative feedback regulation of the secretion of 6 -END 
and ACTH in the Soay ram. The administration of dexamethasone caused a 
decrease in the plasma concentrations of both 6 -END and ACTH at all seasons 
of the year. Furthermore, the administration of the glucocorticoid antagonist, 
RU 486, increased the plasma concentrations of 6 -END and cortisol (indirect 
measure for ACTH) in winter but not in summer. This observation of a 
significant response to RU 486 in winter and not in summer indicates that the 
endogenous glucocorticoids are more inhibitory in winter than in summer, and 
this may partially explain the decline in the plasma concentrations of 6 -END 
and ACTH seen in winter. This study is the first one to use RU 486 as an 
antiglucocorticoid in sheep. The doses used in this experiment had previously 
been used in female monkeys (Macaca fascicularis) (Healy et al., 1985). In this 
species, doses of 1 and 10  mg/kg were shown to cause a significant increase in 
ACTH and cortisol secretion but there was no significant increase in 6 -END 
secretion. The current results show that the dose of 1 mg/kg had no effect on 
the plasma concentrations of both 6 -END and cortisol while that of 10 mg/kg 
significantly increased the plasma concentrations of 6 -END and cortisol in the 
ram. It is not clear whether these discrepancies are due to differences in 
methodology or sex.
The site of action of the negative feedback effect of glucocorticoids 
appears to be the pituitary gland based on the observation that dexamethasone 
pretreatment blocked the ability of AVP to stimulate the secretion of 6 -END 
(experiment 12). This, however, does not exclude an additional negative
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feedback action at the level of the hypothalamus affecting the release of AVP 
and/or CRF as has been demonstrated in the rat (Antoni, 1986; Plotsky et al., 
1986; Carnes et al., 1987). The studies in the ram also show that ACTH and not 
8 -END stimulates the secretion of cortisol. If cortisol is the glucocorticoid 
which normally acts to provide homoeostasis, it follows that the control by 8 - 
END is mediated indirectly via the secretion of ACTH (experiment 13). The 
lack of effect of 8 -END on cortisol secretion does not appear to be a question of 
the dose used because this was selected to result in circulating levels in the 
physiological range seen at the peak of the seasonal cycle (Ebling and Lincoln, 
1987).
The parallel changes in the plasma concentrations of 8 -END and 
ACTH following the acute treatments with AVP, CRF and dexamethasone 
indicate a close link in the regulation of these two hormones, which are possibly 
cosecreted from the corticotrophs in the anterior pituitary gland. This is 
consistent with the observation that the 8 -END in the peripheral circulation in 
the rams is largely in the non-acetylated form as released from the anterior 
p itu itary  gland (Sm ith & Funder, 1988) (chapter 4, experim ent 1). 
Furtherm ore, there was a temporal correlation between the spontaneous 
episodic peaks in the plasma profiles of 8 -END and ACTH. This indicates a 
common control possibly involving the pulsatile release of peptides such as 
AVP and CRF from the hypothalamus.
However, the observation that not all episodic peaks of 6 -END were 
correlated with those of ACTH indicates a more complex control of these two 
pituitary hormones. Detailed studies of the short-term fluctuations in the plasma 
concentrations of 6 -END, ACTH and a-M SH  in Merino sheep have indicated a 
complex differential regulation of these hormones. In particular, only a 
proportion (about 30%) of the episodic peaks in the plasma concentration of
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6 -END was correlated with peaks in the plasma concentration of ACTH and 
some peaks in ACTH occurred with no corresponding increase in either 8 -END 
or a-M SH  (Engler et al., 1989a). These temporal associations indicate that the 
concentration in the peripheral blood is the result of the combined secretion 
from the different cell types in the pituitary gland which process the POMC 
precursor. Since the peaks in the peripheral blood most probably constitute 
secretory episodes induced by the hypothalamus, there must be a hypothalamic 
mechanism which separately regulates the secretion of 8 -END and ACTH. One 
possibility is that there is a seasonal change in the pattern of secretion of AVP 
and CRF, or the ratio of these two peptides in the pituitary portal blood, which 
produces the differential control. To establish this it will be necessary to 
measure the levels of AVP and CRF in the portal blood in the Soay ram at 
different times of the year and correlate this with the seasonal cycle in the 
secretion of 8 -END and ACTH.
5 $  SUMMARY
This second series of experiments has established the following:
1. AVP and CRF stimulate the secretion of 8 -END and ACTH in the 
Soay ram  and the responses are greatest in summer at the time of maximum 
endogenous secretion.
2. Dexamethasone (synthetic glucocorticoid) suppresses the 
secretion of 8 -END and ACTH and the responses are also greatest in summer. 
RU 486 (synthetic glucocorticoid antagonist) stimulates 8 -END and cortisol 
(indirect measure for ACTH) secretion and the responses are greater in winter 
than in summer.
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3. Glucocorticoids act at the level of the pituitary gland to inhibit 
the secretion of 8 -END and ACTH in the Soay ram.
4. ACTH, but not 6 -END, stimulates the secretion of cortisol and 
the response is greater in spring, at the time of high endogenous secretion, than 
at other seasons of the year.
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CHAPTER 6
CONTROL OF THE CYCLE IN 6 -END SECRETION: ROLE OF DA AND
ENDOGENOUS OPIOIDS
M  INTRODUCTION
Both the corticotrophs and melanotrophs of the pituitary gland 
contribute to the total B-END in the peripheral blood (Antoni, 1986; Smith 
and Funder, 1988). The neural control of the secretory activity of the 
corticotrophs has been investigated in chapter 5; this involves stimulation by 
AVP and CRF and inhibition by glucocorticoids. In contrast, the control of 
the secretory activity of the melanotrophs appears to involve an inhibitory 
influence from the hypothalamus. This is based on the observation that 
experimental disconnection of the pituitary gland from the hypothalamus in 
sheep leads to hypertrophy of the intermediate lobe of the pituitary gland and 
an increase in the circulating concentrations of B-END (Clarke et al., 1986). 
In this situation, bromocriptine (DA agonist) suppresses B-END secretion, 
indicating the possible involvement of DA as the inhibitory factor released 
from  the hypothalamus. Indeed, short-term studies in intact sheep have 
established a dopaminergic inhibition upon melanotrophic secretion of 
B-END and a-M SH  (Newman, Wardlaw, Stark, Daniel and Frantz, 1987; 
Smith et al., 1989). Flowever, it is not known whether the results of these 
short-term studies would apply to the long-term control of the cycle in 
B-END secretion in the Soay ram.
The functional activity of the hypothalam o-pituitary-adreno- 
cortical axis is also influenced by endogenous opioid peptides and opiate drugs 
in many species (e.g. frog: Saland et al., 1982b: rat: Buckingham, 1979; 
Buckingham & Cooper, 1984; 1986; sheep: Redekopp et al., 1985a; Wang et 
a l., 1986). However, the results from  the various studies are often 
contradictory. For example, Redekopp et al. (1985a) demonstrated an 
inhibition of ACTH in sheep using the enkephalin analogue, DAMME, while 
Wang et al. (1986) showed that met-enkephalin stimulates the secretion of
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ACTH. Stress is another factor which profoundly influences the the 
hypothalamo-pituitary-adrenocortical axis. For example, in rats, elevated 
plasma levels of 6 -END and ACTH are observed following footshock and 
ether stress, respectively (Rossier et al., 1977; Rivier and Vale, 1983b). In 
sheep, a num ber of stressful stimuli, including acute haem orrhage, 
electroimmobilization and shearing, hypoglycaemia and audiovisual stimulus 
(barking dog), handling, transport and slaughter, have also been shown to 
elevate the plasma levels of 6 -END (chapter 2, section 2.6.2).
The aims of the studies described in this chapter were to 
investigate the inhibitory role of DA in the control of the cycle in 6 -END 
secretion in the Soay ram, and to assess whether endogenous opioids modulate 
this control. A small study was also conducted involving the stress response to 
exposure to a sheep dog. PRL was also monitored since it is well established 
that DA, opioids and stress influence PRL secretion.
6 2  EXPERIMENT 14- EFFECT OF DA. PIMOZIDE AND
NALOXONE ON B-END AND PRL SECRETION
6.2.1 Aim
The aim of this experiment was to assess the effect of DA, pimozide 
(DA antagonist) and naloxone (opioid antagonist) on B-END and PRL secretion 
in rams with low or high endogenous hormone secretion induced by exposure to 
long and short days.
6.2.2 Materials and methods
A group of six adult rams housed indoors was used in this experiment
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carried out both under long days ( 1 0 -1 2  weeks after the change from short to 
long days; low plasma levels of 6 -END and high plasma levels of PRL) and under 
short days ( 1 0 -1 2  weeks after the change from long to short days; high plasma 
levels of 6 -END and low plasma levels of PRL). On both occasions, the animals 
were treated i.v. with DA and naloxone in the first part of the experiment (10 
weeks), and with naloxone and pimozide in the second part of the experiment (1 2  
weeks). The treatment design and bleeding protocol was as follows:
Part one : on day 1, the animals were blood sampled at 10 min intervals for 4h 
before and 4h after the i.v. injection of naloxone given at a dose of 1.6 mg/kg; the 
dose of naloxone was selected on the basis of previous studies in sheep (Lincoln 
& Ebling, 1985; Lincoln et al., 1987). On day 2, this was repeated but the animals 
also received i.v. injections of DA at a dose of 6 .6  |ig/kg everylO min throughout 
the 8h period (total dose 316.8 jig/kg); the dose of DA was also selected on the 
basis of previous studies in sheep (Deaver & Dailey, 1982).
Part two : on day 1, the animals were blood sampled at 10 min intervals for 4h 
before and 4h after the i.v. injection of naloxone given at a dose of 1.6 mg/kg. On 
day 2 , this was repeated but the animals also received i.m. injections of pimozide 
at a dose of 0.08 mg/kg every 2h throughout the 8 h period (total dose 0.32 
mg/kg); the dose of pimozide was selected on the basis of previous studies in 
sheep (Meyer & Goodman, 1985; 1986 ).
Plasma concentrations of 6 -END and PRL were measured by RIA as 
previously described (chapter 3, section 3.4). The results were analysed by 
calculating the mean plasma concentrations of 6 -END and PRL for each 
treatment, based on 10 min samples collected for 4h-periods after the initiation 
of each treatment, and the statistical significance of the treatments was assessed 
by ANOVA (chapter 3, section 3.5).
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The effects of DA, pim ozide and naloxone on the plasm a 
concentrations of 6 -END and PRL under long days and short days are illustrated 
in Fig. 6.1 and in Fig. 6.2, respectively. Under long days, the i.v. injections of 
DA did not significantly affect the mean plasma concentrations of 6 -END and 
PRL assessed over the 4h period after the initiation of the treatment; however, 
there was a small increase in the plasma levels of 6 -END within 1.5h of its 
adm inistration. The i.v. injection of naloxone did not affect the plasma 
concentrations of 6 -END and PRL; nor did naloxone given at the same time as 
DA have an effect on the plasma levels of the two hormones (Fig. 6.1(a)). The
i.m. injections of pimozide caused a significant (P< 0.001, ANOVA) increase in 
the plasma concentrations of 6 -END and PRL compared with the corresponding 
saline control period; the levels became significantly increased lh  after the first 
pimozide injection and remained markedly increased throughout the rest of the 
study. The injection of naloxone at the same time as pimozide did not affect the 
plasma concentrations of 6 -END and PRL (Fig. 6.1(b)).
Under short days, the i.v. injections of DA and naloxone did not 
influence the plasma concentrations of 6 -END and PRL (Fig. 6.2(a)). The i.m. 
injections of pimozide had no effect on the plasma concentrations of 6 -END and 
PRL. However, the injection of naloxone at the same time as pimozide caused a 
significant (P < 0.05, ANOVA) increase in the plasma concentrations of 6 -END 
and PRL (Fig. 6.2(b)).
There was a minor behavioural effect after the second and subsequent 
injections of pimozide; this involved the animals lowering their heads and 
shivering for about 20 min after each injection. This effect was more evident 
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6.3 EXPERIMENT 15- EFFECT OF DA AND NALOXONE ON
fi-END AND PRL SECRETION
6.3.1 Aim
In this experiment, a 10-fold higher dose of DA was used than in the 
previous study to assess whether this will inhibit 6 -END and PRL secretion.
6.3.2 Materials and methods
The six adult rams used to study the effect of DA, pimozide and 
naloxone (experiment 14) were employed in this experiment during a different 
photoperiodic cycle. The experiment was carried out both under long days (10 
weeks after the change from short to long days; low plasma levels of 6 -END and 
high plasma levels of PRL) and under short days (10 weeks after the change from 
long to short days; high plasma levels of 6 -END and low plasma levels of PRL). 
On both occasions, the animals were treated i.v. with DA and naloxone and the 
treatment design and bleeding protocol was as follows: on day 1 , the animals 
were blood sampled at 10 min intervals for 4h before and 4h after the i.v. 
injection of naloxone given at a dose of 1.6 mg/kg. On day 2, this was repeated but 
the animals also received i.v. injections of DA at a dose of 66  pg/kg every 10 min 
throughout the 8h period (total dose 3168 pg/kg).
Plasma concentrations of 6 -END and PRL were measured by RIA as 
previously described (chapter 3, section 3.4). The results were analysed by 
calculating the mean plasma concentrations of 6 -END and PRL, based on 10 min 
samples collected for 4h-periods after the initiation of each treatment, and the 
significance of the treatments was assessed by ANOVA (chapter 3, section 3.5).
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6.3.3 Results
The effects of DA and naloxone on the plasma concentrations of 
6 -END and PRL under long days and short days are illustrated in Fig. 6.3 and 
Fig. 6.4, respectively. The i.v. injections of DA at the high dose decreased the 
plasma concentrations of 6 -END and PRL both under long and short days. 
However, this decrease was not statistically significant (Figs. 6.3 and 6.4). The
i.v. injection of naloxone did not affect the plasma concentrations of 6 -END and 
PRL as previously demonstrated (Figs. 6.3 and 6.4).
6 A  EXPERIMENT 16- EFFECT OF ACUTE BROMOCRIPTINE
TREATMENT ON 6 -END AND PRL SECRETION
6.4.1 Aim
In this experiment, the DA agonist, bromocriptine, which has high
affinity for D2  DA receptors was used to further assess the possible role of DA in 
the inhibitory control of 6 -END and PRL secretion.
6.4.2 Materials and methods
A group of eight adult rams housed indoors was used in this
experiment. The rams were treated s.c. with bromocriptine while maintained 
under long days (1 2  weeks after the change from short to long days; low plasma 
levels of 6 -END and high plasma levels of PRL) or short days (12 weeks after the 
change from long to short days; high plasma levels of 6 -END and low plasma 
levels of PRL). The treatment design and bleeding protocol was as follows: on 
day 1, the animals were blood sampled at 10 min intervals for 8h. On day 2, the 
animals were sampled in the same way but were treated with a s.c. injection of
139-
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bromocriptine was given at a dose of 0.06 mg/kg. The dose of bromocriptine was 
selected based on previous studies in sheep ( McNeilly & Land, 1979 ).
The plasma concentrations of 6 -END and PRL were measured by 
RIA as previously described (chapter 3, section 3.4). The results were analysed 
by calculating the mean plasma concentrations of B-END and PRL based on 10 
min samples collected for the 8h period after the bromocriptine injection, and the 
significance of the treatment was assessed by ANOVA (chapter 3, section 3.5).
6.4.3 Results
The effect of the s.c. injection of bromocriptine on the plasma 
concentrations of B-END and PRL under long days and short days is illustrated in 
Fig. 6.5 and in Fig. 6 .6 , respectively. Under long days, the acute treatment with 
bromocriptine did not significantly affect the plasma concentrations of B-END 
although there was a small decline in the plasma levels of B-END from 4h to 8h 
post-treatment. In contrast, the s.c. injection of bromocriptine caused an abrupt 
and significant (P < 0.001, ANOVA) decrease in the plasma concentrations of 
PRL; the levels became significantly suppressed within 60 min of the injection 
and progressively declined to undetectable levels (< 0.4 ng/ml) by the end of the 
study (Fig. 6.5).
U nder short days, the acute treatm ent with brom ocriptine 
significantly (P < 0.001, ANOVA) decreased the plasma concentrations of B- 
END ; the levels became significantly suppressed within 60 min of the injection 
and progressively declined throughout the rest of the study. There was also a 
significant (P < 0.05, ANOVA) decrease in the plasma concentrations of PRL 
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6.5 EXPERIMENT 17- EFFECT OF CHRONIC BROMOCRIPTINE
TREATMENT AND STRESS ON B-END AND PRL SECRETION
6.5.1 Aim
The aim of this experiment was to investigate the effect of the chronic
administration of bromocriptine on 6 -END and PRL secretion. Also to assess 
whether stress-induced increases in 6 -END and PRL secretion after exposure to 
a sheep dog can be blocked by treatment with bromocriptine.
6.5.2 Materials and methods
The eight indoor rams used to study the effect of acute bromocriptine
(experiment 15) were employed in this study during a different photoperiodic 
cycle.. The animals were treated s.c. with bromocriptine while maintained under 
long days (15 weeks after the change from short to long days; low plasma levels 
of 6 -END and high plasma levels of PRL) or under short days (15 weeks after 
the change from long to short days; high plasma levels of 6 -END and low plasma 
levels of PRL). The treatment design and bleeding protocol was as follows: on 
day 1, the animals were blood sampled at 10 min intervals for 4h before and 2h 
after the exposure to the sheep dog. For this, each individual ram was removed 
from his pen and herded along a corridor by a sheep dog for 5 min. On days 2-6, 
the animals received a daily injection of bromocriptine given at a dose of 0.06 
mg/kg, and on day 7 , the animals received a single injection of bromocriptine 
(0.06 mg/kg) after taking the first blood sample and the protocol involving 
exposure to the sheep dog was repeated as on day 1 .
Plasma concentrations of 6 -END and PRL were measured by RIA as 
previously described (chapter 3, section 3.4). To assess the effect of chronic 
treatment with bromocriptine, mean plasma concentrations of 6 -END and PRL 
were calculated based on 10 min samples collected for 4h-periods before
149.
exposure to the sheep dog; and to assess the effect of exposure to the sheep dog, 
mean plasma concentrations were calculated based on 10 min samples collected 
for lh-periods before and after the exposure to the dog. The statistical 
significances of the treatment with bromocriptine and that of the effect of 
exposure to the sheep dog were assessed by ANOVA (chapter 3, section 3.5).
6.5.3 Results
The effects of chronic treatment with bromocriptine and the effect of 
stress induced by the sheep dog on the plasma concentrations of 6 -END and PRL 
under long days and short days are illustrated in fig. Fig. 6.7 and in Fig. 6 .8 , 
respectively . Under long days, chronic treatm ent w ith brom ocriptine 
significantly (P < 0.01, ANOVA) decreased the plasma concentrations of 
6 -END. There was also a significant (P < 0.001, ANOVA) decrease in the plasma 
concentrations of PRL and the levels became undetectable (< 0.4 ng/ml) after 6 
days of treatment (Fig. 6.7). The stimulus of the sheep dog significantly (P < 
0.001, ANOVA) increased the plasma concentrations of 6 -END both before and 
after the chronic treatment with bromocriptine, with no difference between the 
6 -END responses on the two occasions ( Fig. 6.7). The stimulus of the sheep dog 
also significantly (P < 0.001, ANOVA) increased the plasma concentrations of 
PRL before the chronic treatment with bromocriptine; but there was no response 
after the chronic treatment with bromocriptine ( Fig. 6.7).
Under short days, the chronic treatm ent w ith brom ocriptine 
significantly (P < 0.005, ANOVA) decreased the plasma concentrations of 
6 -END. The plasma concentrations of PRL were already very low on this 
occasion and chronic treatment with bromocriptine produced no effect. The 
stimulus of the sheep dog significantly (P< 0.05, ANOVA) increased the plasma 
concentrations of 6 -END both before and after the chronic treatment with 
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The 6 -END responses were reduced compared with those seen under long days. 
The stimulus of the sheep dog also significantly (P < 0.001, ANOVA) increased 
the plasm a concentrations of PRL before the chronic treatm ent with 
bromocriptine, but there was no response after the treatment (Fig. 6 .8 ).
M  EXPERIMENT 18- EFFECT OF SULPIRIDE ON B-END AND
PRL SECRETION
6.6.1 Aim
Having shown that bromocriptine, a D2  DA agonist, significantly 
inhibited the secretion of B-END and PRL, the aim of this experiment was to 
investigate the effects of sulpiride, a D2  DA antagonist on B-END and PRL 
secretion.
6.6.2 Materials and methods
The eight indoor rams used to study the effect of bromocriptine
(experiments 16 and 17) were employed in this experiment during a different 
photoperiodic cycle.. The rams were treated s.c. with sulpiride while maintained 
under long days ( 9 weeks after the change from short to long days; low plasma 
levels of B-END and high plasma levels of PRL ) or short days (9 weeks after the 
change from long to short days; high plasma levels of B-END and low plasma 
levels of PRL). The treatment design and bleeding protocol was as follows: on 
day 1, the animals were blood sampled at 10 min intervals for 8h. On day 2, the 
animals were blood sampled in the same way but were treated with a s.c. 
injection of sulpiride given at a dose of 0.59 mg/kg. The dose of sulpiride was 
selected based on previous studies in women (McMurdo, McEwen, Lewis, 
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Plasma concentrations of B-END and PRL were measured by RIA as 
previously described (chapter 3, section 3.4). The results were analysed by 
calculating the mean plasma concentrations of B-END and PRL based on 10 min 
samples collected for the 8h period after the sulpiride injection, and the statistical 
significance of the treatment was assessed by ANOVA (chapter 3, section 3.5).
6.6.3 Results
The effect of sulpiride on the plasma concentrations of B-END and 
PRL under long days and short days is illustrated in Fig. 6.9 and in Fig. 6.10, 
respectively. Under long days, the s.c. injection of sulpiride significantly (P < 
0.005, ANOVA) increased the plasma concentrations of B-END; the levels 
became significantly increased within 10  min of the injection and remained 
elevated throughout the rest of the study. There was also a significant (P < 0.001, 
ANOVA) increase in the plasma concentrations of PRL after the s.c. injection of 
sulpiride; the PRL levels became significantly increased within 10 min of the 
injection and remained elevated for 6.5h before declining to baseline (Fig. 6.9).
Under short days, the s.c. injection of sulpiride also significantly (P < 
0.005, ANOVA) increased the plasma concentrations of B-END; the levels 
became significantly increased within 40 min of the injection and remained 
elevated throughout the rest of the study ( Fig. 6.10). There was a significant (P <
0.005, ANOVA) increase in the plasma concentrations of PRL after sulpiride 
treatment; the levels became significantly increased within 2 0  min of the 
injection and remained elevated for 7h before declining to baseline (Fig. 6.10 .
61  DISCUSSION
The studies described in this chapter illustrate that acute and
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chronic treatment with bromocriptine inhibited B-END and PRL secretion; 
the effect on B-END was not so dramatic as for PRL but was evident 
especially under short days when endogenous secretion is increased 
(experiment 16 and 17). These results provide evidence for the involvement 
of DA in the control of B-END and PRL secretion in the Soay ram, and are 
consistent with the studies in Merino sheep (Engler et al., 1989a; Smith et al., 
1989). The observation that both B-END and PRL were inhibited by 
bromocriptine treatment suggests that the action of DA on these two pituitary 
hormones is mediated by D2  receptors. Support for this view is derived from 
studies in which both cAMP production and a -M S H  secretion from the 
intermediate lobe cells were measured in response to both D i- and D2 - 
receptor-specific dopaminergic analogues (Munemura et al., 1980b; Beaulieu, 
Felder & Kebabian, 1986). These studies clearly demonstrated that the 
inhibitory effect of bromocriptine on a-M SH secretion is a D2 -receptor- 
mediated event. Since a -M S H  and B-END are co-secreted from the 
intermediate lobe cells, it is reasonable to conclude that D2  receptors are 
involved in B-END secretion. With regard to PRL, recent evidence has shown 
that the capacity  of brom ocriptine to reduce phosphoinositide 
phosphorylation is a unique property of the D2 -receptor, representing an 
aspect of the chronic mechanism by which DA inhibits PRL release (Jarvis, 
Judd & MacLeod, 1988 ).
The wide spectrum DA antagonist, pimozide, increased B-END 
and PRL secretion both under long and short days (experiment 14). The 
concomitant increase in the secretion of B-END and PRL after pimozide 
treatment indicates that endogenous DA inhibits the secretion of these two 
pituitary hormones; which is consistent with previous studies in other breeds 
of sheep (M eyer & Goodman, 1985). The more specific D2  recep tor 
antagonist, sulpiride, also increased B-END and PRL secretion both under
161.
long and short days, which provides more evidence for the role of DA in the 
control of 6 -END and PRL secretion (experiment 18). These results also 
render further proof that the D2  receptor is involved in the regulation of 
6 -END and PRL secretion in the Soay ram.
The i.v. injections of DA had no effect on 6 -END and PRL 
secretion both under long and short days (experiments 14 and 15). This lack 
of effect by exogenous DA could have been due to degradation of the amine 
before reaching its receptors. Previous studies have shown that it may be 
necessary to use degradation enzyme blockers or antioxidants such as 
pargyline and ascorbic acid (as done in in vitro studies) in order to observe an 
effect (Lewis, Dieguez, Lewis and Scanlon, 1987; Jarvis et al., 1988). 
Alternatively, the lack of effect by DA on B-END and PRL secretion could 
have been due to the mode of DA administration. DA infused every min, at a 
dose similar to that used in experiment 14 and without the addition of enzyme 
blockers or antioxidants, has been shown to significantly reduce the plasma 
concentrations of PRL in crossbred sheep (Deaver & Dailey, 1982). 
Furthermore, Thomas, Cummins, Smythe, Gleeson & Clarke (1986) have 
shown a 70% reduction in plasma levels of PRL in hypothalamo-pituitary 
disconnected Merino sheep infused with DA every min. Thus, the possibility 
that DA administered every min instead of every 10 min may have been 
effective cannot be discounted.
The 6 -END in the peripheral circulation is derived from both the 
anterior and intermediate lobes of the pituitary gland, and it is likely that DA 
affects the secretion in both lobes. Hypothalamic DA neurons are known to 
regulate circulating levels of B-END by directly inhibiting hormone secretion 
from the intermediate lobe (Chen et al., 1983; Farah & Mueller, 1989). In 
contrast, the anterior lobe is not directly innervated by dopaminergic neurons 
(Vermes et al., 1980; Farah & Mueller, 1989); thus, the action of DA on the
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anterior lobe is mediated either humorally via the hypohysial portal system or 
centrally within the central nervous system. So far no DA receptors have been 
identified on anterior lobe corticotrophs that secrete 8 -END, and a very 
recent study has reported an absence of DA in the hypophysial portal blood in 
sheep (Thomas et al., 1989). These two observations rule out the humoral 
action of DA in sheep. Therefore, the influence of DA on anterior lobe 
corticotrophs must be centrally mediated by its action on some other 
hypothalamic substances, most likely AVP and CRF, the two principal 
physiological regulators of 8 -END secretion from the anterior lobe. In 
support of this view is the report that DA inhibits the secretion of CRF in vitro 
in the rat (Hillhouse, Burden & Jones, 1975). Moreover, it has also been 
demonstrated in the rat that the ability of the D2  DA agonist, LY 141865, to 
influence circulating levels of 8 -END is blocked by pretreatment with 
dexam ethasone, which predom inantly inhibits anterior lobe but not 
intermediate lobe secretion of POMC-derived peptides (Farah & Mueller, 
1989). This is a central action mediated by the CRF pathway.
The studies also illustrate that there was no evidence for opioids 
involvement in the control of 8 -END and PRL secretion as judged by the 
administration of naloxone alone. However, they provide evidence that an 
interaction between naloxone and pimozide occurred, indicating that opioids 
play an inhibitory role in 8 -END and PRL secretion in the Soay ram.. An 
interaction between opioids and DA on PRL secretion has previously been 
reported in the rat, involving both a stimulatory and inhibitory action. For 
example, administration of opioids systemically, i.c.v. or into discrete brain 
regions elevates hypophysial portal blood levels of DA and suppresses the 
plasma levels of PRL (Haskins et al., 1981; Johnson, 1982; Reymond et al., 
1983). On the other hand, opioids have been shown to inhibit the turnover, 
synthesis and release of DA in the hypothalamus (Deyo et al., 1979; Van Loon
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et al., 1980a; Wilkes and Yen, 1980), with a resultant increase in PRL 
secretion (Van Loon et al, 1980b). Thus, opioids appear to modulate the effect 
of DA on B-END and PRL secretion.
Stress increased 8 -END and PRL secretion before the chronic 
treatment with bromocriptine (experiment 17). After the treatment, however, 
the stress-induced increase in PRL secretion was inhibited while that in 8 - 
END secretion was not blocked. This indicates differential control of 8 -END 
and PRL systems and may partially explain the lack of correlation between the 
cycle in 8 -END secretion and that in PRL secretion. The anterior lobe 
corticotrophs are stimulated by a number of hypothalamic factors such as 
AVP, CRF, oxytocin and adrenaline which are secreted into the hypophysial 
portal circulation in response to stress (Plotsky et al., 1985; Antoni, 1986). In 
contrast, the intermediate lobe melanotrophs are stimulated by increases in 
circulating adrenaline that occur during stress, and this effect is mediated via 
the 8 -adrenergic receptors (Antoni, 1986). The stress-induced increase in 8 - 
END secretion could have involved any of these factors. The view that AVP 
and CRF were involved is supported by the recent study of Engler et al. 
(1989b) who demonstrated that a 3-min audiovisual stress (barking dog) 
rapidly increased the concentrations of AVP and CRF in the hypohysial portal 
circulation of conscious sheep. However, the observation by Donald et al.
(1983) that CRF does not affect PRL secretion suggests the involvement of 
other hypothalamic factors in the PRL response to stress. This conclusion is 
partially supported, again, by the studies of Engler et al. (1989b) who noted 
an absence of a strict 1:1 concordance between hypothalamic AVP/CRF 
release and that of ACTH secretion during stress. These workers concluded 
from this observation that the release of additional hypothalamic ACTH 
secretagogues were partly responsible for this lack of concordance. 
Therefore, there is a strong possibility that heterogeneous hypothalamic 
responses were elicited by the sheep dog to increase the secretion of both
B-END and PRL in the current study.
The series of experiments described in this chapter was carried out 
both under long and short days to establish whether the inhibitory action of 
DA and the modulatory influence of endogenous opioids change relative to a 
change in photoperiod. The acute administration of pimozide caused a greater 
increase in the secretion of B-END and PRL under long days than under short 
days, which may suggest a greater inhibitory influence of endogenous DA 
over B-END and PRL secretion under long days. While this may be true for 
B-END, accounting for the low plasma levels of B-END observed under long 
days, it is not true for PRL since there are higher plasma levels of PRL under 
long days than under short days. The administration of sulpiride caused a 
sim ilar response in B-END secretion both under long and short days; 
however, the response in PRL secretion was greater and more sustained under 
long days than under short days. Furthermore, the injection of naloxone at the 
same time as pimozide significantly increased the plasma concentrations of 
B-END and PRL under short days but not under long days. This effect 
suggests a greater inhibitory influence of endogenous opioids on B-END and 
PRL secretion under short days. However, as for the effect of pimozide, this 
seems to be true only for PRL secretion, probably accounting, in part, for the 
low plasma levels of PRL observed under short days, but it does not appear to 
be true for B-END since there are higher plasma levels of B-END under short 
days than under long days. These observations indicate that the action of 
endogenous DA and its interaction with endogenous opioids on B-END and 
PRL secretion as related to photoperiod appears to involve more complex 
mechanisms on a long-term basis, which may further highlight the lack of 
correlation between the cycle in B-END secretion and that in PRL secretion.
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6.8 SUMMARY
This third series of experiments has established the following:
1. Bromocriptine (specific D2  agonist) inhibits the secretion of B- 
END and PRL in the Soay ram, and the response in B-END secretion is 
greater under short days while that in PRL secretion is greater under long 
days.
2. Pimozide (non-specific DA antagonist) increases the secretion 
of B-END and PRL and the responses are greater under long days than under 
short days.
3. Sulpiride (specific D2 antagonist) increases the secretion of 
B-END and PRL, and the response in B-END secretion is similar under long 
and short days for B-END while that in PRL secretion is greater under long 
days than under short days.
4. Endogenous opioids interact with DA under short days to 
increase the secretion of B-END and PRL.
5. Acute stress increases the secretion of B-END and PRL, and the 
responses are greater under long days than under short days.
CHAPTER 7 
GENERAT, DISCUSSION
1 6 7 .
The current study demonstrates that Soay rams show a conspicuous 
seasonal cycle in the peripheral plasma concentrations of B-END; the levels of 
B-END are 10-to-20 times higher in summer and autumn than in winter and 
spring, which is consistent with a pattern previously described for Soay rams 
(Ebling and Lincoln, 1987). Merino rams do not show a seasonal cycle in B- 
END secretion and crossbred rams, produced by mating Soay ewes with a 
Merino ram, show a seasonal cycle in B-END secretion intermediate in 
amplitude between that characterisctic of the parents, demonstrating the genetic 
basis for the differences between the Soay and Merino breeds. The breed 
variation reflects a different degree of seasonality between the Soay and 
Merino sheep. The Soay sheep are semi-domesticated and show marked 
seasonality in physiology and behaviour like their ancestors, the wild 
Mouflons. They are very seasonal in appetite, body growth, moulting, fattening 
and reproduction (Ryder, 1971; Argo and Smith, 1983; Lincoln and Ebling, 
1985; Ebling and Lincoln, 1987; Lincoln, 1989b,c). On the other hand, Merino 
sheep are domesticated animals originating from the Mediterranian areas, and 
are selected for production of fine wool, which grows continuously throughout 
the year. They do not show a seasonal cycle in moulting and also have a less 
conspicuous seasonality in reproduction (Amir and Volcani, 1965; Barrell and 
Lapwood, 1978/1979; Ryder, 1983; Lincoln, 1989c). The putative role of B- 
END in the control of aspects of metabolism fits in with the breed differences. 
In the Soay sheep, the plasma levels of B-END peak in autumn, coinciding with 
a phase of maximum body weight and fattening. This is an adaptation in which 
B-END participates to regulate body resources and energy in order for the 
animals to survive through winter when food supply is limited.
The studies on outdoor rams revealed that there is a seasonal cycle 
in the peripheral plasma concentrations of ACTH and cortisol; the levels were 
minimum in winter and maximum in summer, about 2  months in advance of 
the peak in B-END secretion. Furthermore, the studies involving the treatments
168.
with AVP, CRF, dexamethasone and RU 486 indicated a parallel control of 8 - 
END and ACTH. AVP and CRF stimulated the secretion of both B-END and 
ACTH while dexamethasone suppressed and RU 486 enhanced their secretion. 
The seasonal changes in the responses to all these treatments occurred in 
parallel for both B-END and ACTH, and a close analysis of endogenous 
secretion revealed a temporal correlation between some of the endogenous 
pulses in the plasma profiles of B-END and those of ACTH secretion. All these 
observations provide evidence that B-END and ACTH are cosecreted from the 
corticotrophs of the anterior pituitary gland. This is consistent with the 
observation that most circulating B-END is non-acetylated as released from the 
anterior pituitary gland (Antoni, 1986; Smith and Funder, 1988). Since the 
pituitary gland contains higher amounts of B-END than the brain and 
peripheral tissues (Ebling and Lincoln, 1987; Ebling et al., 1987; Smith and 
Funder, 1988), the major source of circulating B-END in the Soay ram seems 
to be the anterior pituitary gland.
The control of the secretory activity of the anterior lobe 
corticotrophs involves stimulation by AVP and CRF from the hypothalamus 
and inhibition by glucocorticoids from the adrenal gland. The seasonal cycle in 
B-END secretion may, therefore, be dictated by a seasonal change in the 'drive' 
from the hypothalamus which stimulates an increase in the secretory activity of 
corticotrophs in summer and autumn, or may be due to a seasonal change in the 
negative feedback control from the adrenal gland which inhibits the secretory 
activity of corticotrophs in winter and spring. However, the control of the 
seasonal cycle in B-END secretion is apparently more complex as this simple 
interpretation does not account, for example, the notable difference in the 
timing of the seasonal cycle in B-END and ACTH secretion. The seasonal 
increase in the plasma concentrations of ACTH occurred in advance of that for 
B-END, and the seasonal maximum was 2 months earlier in the year. This
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difference in the release of the two anterior pituitary hormones may involve 
changes in the activity of the corticotrophs which preferentially secrete ACTH 
in summer and B-END in autumn. This may result from a seasonal change in 
the processing of the POMC precursor in the corticotrophs related to the level 
of hypothalamic stimulation and glucocorticoid feedback, or a seasonal change 
in the subpopulations of corticotrophs which may respond to a change in the 
ratio of AVP:CRF to secrete more B-END or ACTH. An alternative 
explanation for the differential regulation, is that there is a separate control of 
the corticotrophs in the anterior pituitary gland which secrete ACTH in 
summer, and the melanotrophs in the intermediate lobe of the pituitary gland 
which secrete B-END in the autumn.
The melanotrophs in the intermediate lobe of the pituitary gland 
form an additional contribution to the circulating pool of B-END. They are 
under the inhibitory control of DA (Farah et al., 1982; Chen et al., 1983; 
Newman et al., 1987; Smith et al., 1989). The current studies, using the DA 
agonist, bromocriptine, and the DA antagonists, pimozide and sulpiride, 
illustrate the role of DA in the inhibition of B-END secretion. Bromocriptine 
decreased the plasma concentrations of B-END while both pimozide and 
sulpiride increased B-END secretion. The results obtained with the specific D2 
receptor DA antagonist, sulpiride, provide further evidence as to which DA 
receptor type is involved in the action of DA. Thus, it is likely that the DA 
system is involved in the control of the secretory activity of melanotrophs in 
the Soay ram, and a seasonal change in the activity of hypothalamic 
dopaminergic neurons may influence the seasonal cycle in B-END secretion by 
causing differential secretion of B-END from melanotrophs as opposed to the 
secretion from the corticotrophs. Detailed studies of the short-term 
fluctuations in the plasma concentrations of B-END, ACTH and a-M SH  in 
Merino sheep have also indicated a complex differential regulation of these
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hormones. In particular, only a proportion (about 30%) of the episodic peaks 
in the plasma concentrations of B-END was correlated with peaks in the plasma 
concentrations of ACTH and some peaks in ACTH occurred with no 
corresponding increase in either B-END or a -M S H  (Engler et al., 1989a). 
These temporal associations indicate that the hormone concentrations in the 
peripheral blood is the result of the combined secretion from the corticotrophs 
and melanotrophs which process the POMC precursor in the two lobes of the 
pituitary gland.
Based on the current results and a survey of the relevant literature, a 
model is proposed to explain the control of the seasonal cycle in B-END 
secretion in the Soay ram, and a simplistic illustrtation is given in Fig. 7.1. In 
this model, hypothalamic AVP, CRF and DA, and adrenal cortisol are 
involved. On one hand, AVP and CRF stimulate the release of B-END and 
ACTH from the anterior pituitary gland. ACTH, but not B-END, stimulates the 
adrenal gland to release cortisol, which, in turn, negatively regulates the 
secretion of B-END and ACTH from the anterior pituitary gland as well as 
inhibiting the release of AVP and CRF from the hypothalamus. On the other 
hand, DA inhibits the release of B-END and a-M SH  from the intermediate 
pituitary gland. W ithin the hypothalamus, there is a possibility of DA 
influencing the secretion of B-END by inhibiting the release of AVP and CRF 
(Farah et al., 1982; Murburg et al., 1986), and endogenous opioids may control 
the secretion of B-END by modulating the release of AVP, CRF and DA from 
the hypothalam us (Buckingham, 1982; Buckingham  and Cooper, 1984; 
Murburg et al., 1986). For example, opiates have been shown to stimulate CRF 
(Buckingham and Cooper, 1986), and to either stimulate (Haskins et al., 1981; 
Johnson, 1982) or inhibit (Deyo et al., 1979; Wilkes and Yen, 1980; Reymond 
et al., 1983) the release of DA. The extent to which these different mechanisms 
participate in the control of B-END secretion apparently vary relative to a
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Fig. 7.1. A model proposed to explain the control of the seasonal cycle in 
B-endorphin secretion in the Soay ram, based on the current study and the 
relevant literature, i) Hypothalamic AVP and CRF stimulate the secretion of 
B-endorphin and ACTH from the anterior pituitary gland., ACTH stimulates 
the adrenal gland to secrete cortisol, which, in turn, directly inhibits the 
secretion of B-enorphin and ACTH from the pituitary gland and indirectly 
inhibits he release of AVP and CRF from the hypothalamus, ii) Dopamine 
inhibits the secretion of B-endorphin from the intermediate pituitary gland, 
and within the hypothalamus, there is a possibility of dopamine influencing the 
secretion of 6 -endorphin from the anterior pituitary gland by inhibiting the 
release of AVP and CRF. Endogenous opioid peptides may also influence the 
secretion of B-endorphin by modulating the release of AVP, CRF and 
dopamine from  the hypothalamus. The extent to which these different 
mechanisms participate in the control of B-endorphin secretion varies between 
summer and winter relative to the change from summer and winter. In 
summer, the hypothalamus releases a lot of CRF and AVP which cause greater 
secretion of B-endorphin and ACTH from the anterior pituitary gland. The 
ACTH stimulates greater quantities of cortisol which inhibit B-endorphin and 
ACTH secretion at the pituitary and hypothalamic levels. The stimulatory 
hypothalamic drive seems to override the inhibitory action of cortisol in 
summer. Dopamine is less inhibitory in summer, leading to some B-endorphin 
being secreted from the intermediate pituitary gland. A change from summer 
to winter reduces the CRF and AVP drive but increases the sensitivity of the 
anterior pituitary gland and CRF and AVP neurons to the inhibitory action of 
cortisol; the inhibitory action of dopamine is also increased from summer to 
winter. The end result is a reduction in the plasma concentrations of 6 - 
endorphin in the peripheral circulation. A= anterior; 1= intermediate; P= 
posterior.
SUM M ER W IN T E R
change from  summer to winter as illustrated in Fig. 7.1. In summer, the 
hypothalamus releases a lot of CRF and AVP which cause greater secretion of 
6 -END and ACTH from the anterior pituitary gland. The ACTH stimulates 
greater quantities of cortisol which inhibits the secretion of 6 -END and ACTH 
at the pituitary and hypothalamic levels. The stimulatory hypothalamic drive of 
CRF and AVP seems to override the inhibitory action of cortisol in summer. 
DA is less inhibitory in summer, leading to some 6 -END being secreted from 
the intermediate pituitary gland. A change from summer to winter reduces the 
CRF and AVP drive but increases the sensitivity of the anterior pituitary gland 
and CRF and AVP neurons to the inhibitory action of cortisol; the inhibitory 
action of DA is also increased from summer to winter. The end result is a 
decrease in the plasma concentrations of 6 -END in the peripheral circulation. 
The current study could not attribute any role to gonadal steroids in the control 
of 6 -END secretion from the pituitary gland since the cycle in 6 -END secretion 
occurred in castrate and castrate + T rams similar to the situation in intact 
rams.
Photoperiod apparently acts to time the cycle in 6 -END secretion. 
This is illustrated by the effects of artificial photoperiod and melatonin 
treatment; long days caused a decrease in 6 -END secretion while short days 
increased 6 -END secretion, and melatonin implants given under long days 
caused an increase in 6 -END secretion, similar to the effect of short days. 
However, the influence of photoperiod on the seasonal cycle in 6 -END 
secretion seems not to be exclusive as judged by the results from the PINX 
rams. In these animals, the seasonal chnages in 6 -END secretion were still 
evident, albeit with a less well defined pattern, which indicates that other 
environmental cues were operative. A similar situation has been observed in 
PINX and SCGX rams with respect to long-term cycles in pituitary and 
testicular activity (Lincoln et al., 1989a). In this situation, the animals are
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apparently unable to respond to changes in photoperiod in a normal way due to 
the loss of a functional pineal gland but they remain competent to respond to 
other environmental cues such as changes in nutrition and temperature.
Another environmental factor that influences the secretion of 
6 -END is that of stress. The exposure of rams to the sheep dog for 5 min 
significantly increased the plasma concentrations of 6 -END, indicating an 
immediate activation of the hypothalamo-pituitary axis. Stressful farm 
procedures such as handling, transport, electroimmobilization and shearing are 
routinely experienced by sheep. These procedures cause acute stress which is 
associated with increased levels of 6 -END both in cerebrospinal fluid and in the 
peripheral circulation (Nakao et al., 1979; Jephcott et al., 1987; Fordham et al., 
1989); and it has been proposed that secretion of 6 -END during stress may be 
part of the mechanism of stress-induced pain suppression (Akil et al., 1978; 
Shiomi and Akil, 1982; Terenius, 1982). The stress-induced release of 6 -END 
is associated with the activation of the paraventricular hypothalamus, which 
releases a number of neuromodulatory factors, most importantly AVP and 
CRF, that regulate the secretory activity of the pituitary gland (Plotsky et al., 
1985; Antoni, 1986; Engler et al., 1989b). In a seasonal environment, there are 
other environmental factors such as coldness, wettness and lack of food, which 
may have a chronic influence on the hypothalamo-pituitary axis. These various 
factors may also constitute a long-term environmental control over the seasonal 
cycle in 6 -END secretion by acting via the hypothalamus.
In the Soay ram, the plasma concentrations of 6 -END are high in 
summer and autumn and are low in winter and spring. The current evidence is 
consistent with the control of the seasonal cycle in 6 -END secretion by the 
hypothalamus; AVP and CRF stimulate 6 -END secretion from the anterior 
lobe corticotrophs while DA inhibits 6 -END release from the intermediate 
lobe melanotrophs. However, the extent to which these two systems are
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involved in the seasonality of 6 -END secretion is not clear. For example, are 
the marked seasonal changes in 6 -END secretion largely due to seasonal 
changes in the concentrations of AVP and CRF in the hypophysial portal 
system, or are they due to differential processing of the POMC precursor by 
the corticotrophs and melanotrophs at different times of the year?. To 
dissociate these issues, it will be necessary to obtain more detailed evidence, for 
example, on the following. First, on the peptides present in the hypophysial 
portal blood system linking the hypothalamus to the pituitary gland. The 
prediction is that there is an increase in AVP and CRF from spring to autumn 
which constitutes the drive to 6 -END increase at this time of the year. Second, 
on the pattern of secretion of 6 -END, ACTH, a-M SH  and Nac-6 -END in the 
peripheral circulation at different times of the year, and to correlate the 
peripheral pattern of secretion with the seasonal changes in the concentrations 
of AVP and CRF in the hypophysial portal system. Third, on the effects of 
differentially manipulating the content or secretion of corticotrophs and 
melanotrophs, for example, by using specific cytotoxic techniques which 
selectively eliminate one cell type and leave the other type (Schwartz, Penke, 
Rivier and Vale, 1987; Schwartz and Vale, 1988), or by carrying out selective 
adeno- and neurointermedio-hypophysectomy (Przewlocki, Millan, Gramsch, 
Millan and Herz, 1982).
In conclusion, the studies described in this thesis have demonstrated 
that there is a clearly defined cycle in 6 -END secretion in the peripheral blood 
of the Soay ram. The control of this cycle involves complex mechanisms, 
including hypothalamic AVP, CRF, DA and endogenous opioid peptides, and 
adrenal glucocorticoids. Photoperiod and other environmental factors act to 
influence the hypothalamic mechanisms and, thus, modulate 6 -END secretion.
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